WO2010059529A2 - Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof - Google Patents

Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof Download PDF

Info

Publication number
WO2010059529A2
WO2010059529A2 PCT/US2009/064443 US2009064443W WO2010059529A2 WO 2010059529 A2 WO2010059529 A2 WO 2010059529A2 US 2009064443 W US2009064443 W US 2009064443W WO 2010059529 A2 WO2010059529 A2 WO 2010059529A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
veterinarily acceptable
acceptable carrier
composition
Prior art date
Application number
PCT/US2009/064443
Other languages
English (en)
French (fr)
Other versions
WO2010059529A3 (en
Inventor
Mark David Soll
Luiz Gustavo Cramer
Patrice Wurtz
James Pate
Natalya Shub
Loic Patrick Le Hir De Fallois
Philip Reid Timmons
Original Assignee
Merial Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA201107658A priority Critical patent/UA107654C2/ru
Priority to CN200980153974.0A priority patent/CN102271672B/zh
Priority to RU2011124948/15A priority patent/RU2011124948A/ru
Priority to EP12189478.6A priority patent/EP2550962B1/en
Priority to CA2743856A priority patent/CA2743856C/en
Priority to AU2009316899A priority patent/AU2009316899B2/en
Priority to NZ592865A priority patent/NZ592865A/xx
Application filed by Merial Limited filed Critical Merial Limited
Priority to AP2011005959A priority patent/AP3359A/xx
Priority to EP09760661A priority patent/EP2364147A2/en
Priority to JP2011537523A priority patent/JP5755143B2/ja
Priority to BRPI0922043-7A priority patent/BRPI0922043B1/pt
Priority to KR1020117014099A priority patent/KR101660068B1/ko
Priority to MX2011005184A priority patent/MX2011005184A/es
Priority to SG2011035771A priority patent/SG171751A1/en
Priority to TW098139363A priority patent/TWI505777B/zh
Publication of WO2010059529A2 publication Critical patent/WO2010059529A2/en
Publication of WO2010059529A3 publication Critical patent/WO2010059529A3/en
Priority to ZA2011/03618A priority patent/ZA201103618B/en
Priority to IL212938A priority patent/IL212938A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having no bond to a nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention provides veterinary compositions comprising 1-arylpyrazoles, alone or in combination with other active agents, for eradicating ectoparasites and/or endoparasites; the use of these compositions against ectoparasites and/or endoparasites, and methods for preventing or treating parasitic infestations of animals comprising administering the inventive composition of the invention to the animal.
  • compositions comprising a formamidine that exhibit improved stability, and a kit for treating or preventing parasitic infestations in animals, which comprises at least one 1-arylpyrazoles and at least one formamidines in a dual-cavity container.
  • ectoparasites such as insects
  • endoparasites such as filariae and other worms.
  • domesticated animals such as cats and dogs, are often infested with one or more of the following ectoparasites: fleas (Ctenocephalides spp., such as Ctenocephalides felis and the like), ticks (Rhipicephalus spp., Ixodes spp., Dermacentor spp., Amblyoma spp., and the like), - mites (Demodex spp., Sarcoptes spp., Otodectes spp., and the like), lice (Trichodectes spp., Cheyletiella spp., Lignonathus spp.
  • fleas are a particular problem because not only do they adversely affect the health of the animal or human, but they also cause a great deal of psychological stress. Moreover, fleas are also vectors of pathogenic agents in animals, such as dog tapeworm (Dipylidium caninum), and humans.
  • ticks are also harmful to the physical and psychological health of the animal or human.
  • the most serious problem associated with ticks is that they are the vector of pathogenic agents in both humans and animals.
  • Major diseases which are caused by ticks include borrelioses (Lyme disease caused by Borrelia burgdorferi), babesioses (or piroplasmoses caused by Babesia spp.) and rickettsioses (also known as Rocky
  • Ticks also release toxins which cause inflammation or paralysis in the host. Occasionally, these toxins are fatal to the host.
  • mites and lice are particularly difficult to combat since there are very few active substances which act on these parasites and they require frequent treatment.
  • farm animals are also susceptible to parasite infestations.
  • cattle are affected by a large number of parasites.
  • a parasite which is very prevalent among farm animals is the tick genus Boophilus, especially those of the species microplus (cattle tick), decoloratus and annulatus. Ticks, such as Boophilus microplus, are particularly difficult to control because they live in the pasture where farm animals graze.
  • myiases-causing flies such as Derm ⁇ tobi ⁇ hominis (known as Berne in Brazil) and Cochlyomia hominivorax (greenbottle); sheep myiases-causing flies such as Lucilia sericata, Lucilia cuprina (known as blowfly strike in Australia, New Zealand and South Africa). These are flies whose larva constitutes the animal parasite; flies proper, namely those whose adult constitutes the parasite, such as Haematobia irritans (horn fly); lice such as Linognathus vitulorum, etc.; and mites such as Sarcoptes scabiei and Psoroptes ovis.
  • 1-arylpyrazoles as a class of chemicals are well known in the art, and certain compounds in this class have been found to be potently active against a wide range of pests and parasites that are harmful to animals and plants.
  • 1-arylpyrazole derivatives are known in the art to prevent, treat or control ectoparasitic infestations in mammals, such as cats, dogs and cattle.
  • Certain 1-arylpyrazoles and their use against pests are described in US Patent Publication Nos. US 2005/0182048; US 2006/0135778; US 2008/0132487; US 2008/0031902; US Patent Nos.
  • EP 0 234 119 EP 0 295 117, EP 0 352 944, EP 0 500 209, EP 0 780 378, EP 0 846 686, and EP 0 948 485, all of which are incorporated herein by reference in their entirety.
  • Topical administration comprises, in particular, skin solutions (pour-on or spot-on), sprays, drenches, baths, showers, jets, powders, greases, shampoos, creams, etc.
  • the pour-on type skin solutions may be designed for percutaneous administration.
  • milbemycin or avermectin derivatives which are natural or semi-synthetic compounds that contain a 16-membered macrocyclic ring.
  • the avermectin and milbemycin series of compounds are potent anthelmintic and antiparasitic agents against a wide range of internal and external parasites.
  • the natural product avermectins are disclosed in U.S. Patent 4,310,519 to Albers-Schonberg, et al., and the 22, 23-dihydro-avermectin compounds are disclosed in Chabala, et al., U.S. Patent 4,199,569.
  • avermectins which include a discussion of their uses in humans and animals, see "Ivermectin and Abamectin," W.C. Campbell, ed., Springer- Verlag, New York (1989).
  • Naturally occurring milbemycins are described in Aoki et al., U.S. Patent No. 3,950,360.
  • Amitraz is a well-known acaracide/insecticide from the formamidine family acknowledged to be useful as a miticidal agent and for the control of ticks. See Plumb's Veterinary Drug Handbook (Fifth Edition), ed. Donald C. Plumb, Blackwell Publishing, pg. 34, (2005).
  • Amitraz differs from other members of the formamidine family in that there are two such moieties in the compound.
  • Amitraz has the following structure:
  • compositions comprising formamidine compounds including amitraz
  • amitraz has been shown to degrade in aqueous solutions at certain pH ranges, as described, for example, in E. Corta, A. Bakkali, L. A. Berrueta, B. Gallo, F. Vicente, "Kinetics and
  • amitraz as a parasiticide in a commercial veterinary pharmaceutical product.
  • problems include: (1) insufficient stability at certain pH values: while amitraz is stable at higher pH values, amitraz tends to hydrolyze over time at pH ranges commonly associated with physiological use (e.g. pH of about 5.0 to about 6.0); (2) amitraz is not effective for the control of fleas; and (3) compositions comprising amitraz may not provide a sufficiently long term shelf life in mixtures with some antiparisitic agents and certain carriers.
  • compositions containing amitraz may not have sufficient long term stability (shelf life) in certain solvent systems which are optimal for other antiparasitic agents with which it may be combined.
  • a composition comprising a 1-aryl-pyrazole with a formamidine compound, e.g. fipronil with amitraz, which exhibits synergistic efficacy against ectoparasites is described in U.S. Patent No. 7,531,186 to Boeckh et al.; however certain embodiments of the composition, where a 1-arylpyrazole and a formamidine are present together in certain carriers, may not have a sufficiently long storage shelf life.
  • One possible reason for the insufficient long term shelf life is that fipronil is stable at a pH of about 5.0 to about 6.0, while amitraz will degrade at this pH range.
  • compositions comprising amitraz which provide enhanced stability with other active agents, including 1-arylpyrazoles, and improved dissipation of odor.
  • the present invention provides compositions and formulations comprising a 1- arylpyrazole compound or a 1-arylpyrazole compound in combination with a formamidine compound, formulations and uses or veterinary uses thereof for the treatment or prophylaxis of parasitic infestations of animals (either wild or domesticated), including livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle, with the aim of ridding these hosts of parasites commonly encountered by such animals.
  • livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle
  • the invention also provides methods for the treatment or prevention of parasitic infestations in animals, comprising administering an effective amount of a composition comprising at least one 1-arylpyrazole or a 1-arylpyrazole in combination with at least one formamidine compound to the animal.
  • inventive compositions and formulations described herein exhibit superior stability and synergistic efficacy against harmful parasites over a long duration compared to compositions known in the art.
  • the present invention has surprisingly overcome the problems associated with the instability of a formamidine in solution and the problems associated with the instability of a solution comprising a 1-arylpyrazole and a formamidine.
  • compositions or formulations of the invention include spot-on, pour-on or spray formulations and may include a further ectoparasiticide, such as an insect growth regulator (IGR), an avermectin or milbemycin derivative, an acaricide, a pyrethroid insecticide, or an anthelmintic, such as benzimidazoles or imidazothiazoles.
  • IGR insect growth regulator
  • avermectin or milbemycin derivative such as an acaricide, a pyrethroid insecticide, or an anthelmintic, such as benzimidazoles or imidazothiazoles.
  • compositions comprising at lest one l-aryl-5- aklyl or l-aryl-5-haloakylpyrazole compound of formula (IA)
  • variables R 2a , R 3a , R 4a , R ⁇ a and Ri 3a are as defined below, in combination with a veterinarily acceptable carrier, and optionally with at least one crystallization inhibitor.
  • Another object of the invention is to provide a composition for the treatment and prevention of a parasitic infestation in an animal comprising at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier, at least one formamidine compound in a second veterinarily acceptable carrier, and optionally at least one crystallization inhibitor; wherein the 1-arylpyrazole compound(s) and first veterinarily acceptable carrier are isolated and not in fluid communication with the formamidine compound(s) and the second veterinarily acceptable carrier.
  • the 1-arylpyrazole compounds have the formula (IB) shown below, where the variables R 2 b, R ⁇ b, R ⁇ , R ⁇ b and Z are described below.
  • the formamidine compounds in the compositions of the invention have the formula (II) shown below, where variables R 14 , R 15 , Ri 6 , R 17 and x are described below.
  • the invention provides compositions and methods comprising at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier and at least one formamidine compound in a second veterinarily acceptable carrier, where the compounds and veterinarily acceptable carriers are stored and administered from dual-cavity containers.
  • the methods and compositions allow for stable synergistic compositions comprising 1- arylpyrazole compounds and formamidine compounds that have superior activity against parasites.
  • the 1-arylpyrazole compound is fipronil and the formamidine compound is amitraz.
  • the 1-arylpyrazole compound(s) and the corresponding carrier is administered simultaneously with the formamidine compound(s) in a second carrier.
  • the carriers include solvents with dielectric constants of about 2 to about 30 that are acceptable for pharmaceutical and/or veterinary use.
  • the carriers include aprotic solvents or polar aprotic solvents.
  • the carrier includes aprotic solvents or polar aprotic solvents with dielectric constants of about 2 to about 30.
  • the formamidine compositions comprising a mixture of at least two solvents with dielectric constants of about 2 to about 30 exhibit surprisingly improved odor dissipation compared to prior art compositions.
  • the invention also provides a kit for the treatment or prevention of a parasitic infestation in an animal, which comprises at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier, at least one formamidine compound in a second veterinarily acceptable carrier, and a multiple cavity container; wherein the one or more 1-arylpyrazole compound(s) in the first veterinarily acceptable carrier is in a first cavity of the multiple cavity container and the one or more formamidine compound(s) and the second veterinarily acceptable carrier are in a second cavity of the multiple cavity container.
  • Fig. 1 is a side view of an embodiment of a container.
  • Fig. 2 is a side view of an embodiment of a container.
  • Fig. 3 is a side view of an embodiment of a container.
  • Fig. 4 is a side view of an embodiment of a container.
  • Fig. 5 is a top view of an embodiment of a container.
  • Fig. 6 is a top view of an embodiment of a container.
  • Fig. 7 is a top view of an embodiment of a strip of 3 containers.
  • Fig. 8 is a 3CAD view top view of an embodiment of an individual small container.
  • Fig. 9a and 9b are 3CAD views of an embodiment of an individual large container.
  • Fig. 10 shows the effect of fipronil alone, amitraz alone and a fipronil/amitraz combination on the geometric mean of tick motility over time
  • Fig. 11 shows the % efficacy of various compositions of the invention against fleas in dogs.
  • Fig. 12 shows the % efficacy of various compositions of the invention against fleas in cats.
  • the present invention provides novel and inventive compositions and formulations comprising at least one 1-arylpyrazole compound alone or in combination nation with one or more formamidine compound(s) and a veterinarily acceptable carrier or diluent. Also provided are methods and uses for the treatment or prophylaxis of parasitic infections and infestations of animals, comprising administering an effective amount of a composition of the invention to the animal. Surprisingly, it has been found that the inventive compositions and formulations described herein comprising al-arylpyrazole compound alone or in combination with a formamidine compound exhibit superior stability and efficacy, including synergistic efficacy in some embodiments, against harmful parasites.
  • the present invention has surprisingly overcome the problems associated with the lack of long term stability of a formamidine in solution and the problems associated with the insufficient shelf life of a composition comprising a 1-arylpyrazole and a formamidine in certain carriers.
  • the invention includes at least the following features:
  • the invention provides novel compositions comprising at least one 1-arylpyrazole of formula (I), or veterinarily acceptable salts thereof, together with a veterinarily acceptable carrier or diluent, that exhibit superior activity against animal parasites and improved stability;
  • compositions comprising at least one formamidine of formula (II), or veterinarily acceptable salts thereof, together with a veterinarily acceptable carrier or diluent, that exhibit improved stability;
  • veterinary composition comprising at least one 1-arylpyrazole of formula (I) and a formamidine of formula (II), or veterinarily acceptable salts thereof, together with one or more veterinarily acceptable carrier(s) or diluent(s), that exhibits synergistic efficacy against animal parasites and improved stability;
  • compositions comprising at least one formamidine of formula (II), or veterinarily acceptable salts thereof, in a veterinarily acceptable carrier or diluent, wherein the formamidine exhibits superior stability in solution;
  • methods for the treatment or prevention of parasitic infestations in animals comprising administering an effective amount of at least one 1-arylpyrazole of formula (I) and at least one formamidine of formula (II), or veterinarily acceptable salts thereof, together with veterinarily acceptable carriers or diluents, wherein the l-arylpyrazole(s) and the formamidine compound(s) are administered in separate carriers;
  • methods for the treatment or prevention of parasitic infestations in animals comprising administering an effective amount of at least one 1-arylpyrazole of formula (I) and at least one formamidine of formula (II), or veterinarily acceptable salts thereof, together with veterinarily acceptable carriers or diluents, wherein the l-arylpyrazole(s) and the formamidine compound(s) are administered simultaneously;
  • methods for the treatment or prevention of parasitic infestations in animals comprising administering an effective amount of at least one 1-arylpyrazole of formula (I) and at least one formamidine of formula (II), or veterinarily acceptable salts thereof, together with veterinarily acceptable carriers or diluents, wherein the l-arylpyrazole(s) and the formamidine(s) are administered simultaneously and the l-arylpyrazole(s) and the formamidine(s) are in separate carriers;
  • methods for the treatment or prevention of parasitic infestations in animals comprising administering an effective amount of at least one 1-arylpyrazole of formula (I) and at least one formamidine of formula (II), or veterinarily acceptable salts thereof, together with veterinarily acceptable carriers or diluents, wherein l-arylpyrazole(s) and the formamidine(s) are administered simultaneously using a dual-cavity container that holds the
  • a dual-cavity container for storing and administering the compositions of the invention, wherein the container comprises a first cavity defined by a front wall and a divider wall, and a second cavity defined by a rear wall and a divider wall.
  • the compounds of the invention are intended to include all stereoisomers and crystalline forms (which includes hydrated forms, polymorphic forms and amorphous forms with up to 15% by weight crystalline structure) thereof.
  • animal is used herein to include all mammals, birds and fish and also include all vertebrate animals, including humans.
  • Animals include, but are not limited to, humans, cats, dogs, cattle, chickens, cows, deer, goats, horses, llamas, pigs, sheep and yaks. It also includes an individual animal in all stages of development, including embryonic and fetal stages.
  • alkyl refers to saturated straight, branched, cyclic, primary, secondary or tertiary hydrocarbons, including those having 1 to 20 atoms.
  • alkyl groups will include C 1 -C 12 , C 1 -C 1 O, Ci-Cs, Ci-C 6 or C 1 -C 4 alkyl groups.
  • C 1 -C 1 O alkyl examples include, but are not limited to, methyl, ethyl, propyl, 1-methylethyl, butyl, 1- methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3- methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1,1-dimethylpropyl, 1,2- dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1- dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl,
  • Cyclic alkyl groups which are encompassed by alkyl, may be referred to as "cycloalkyl" and include those with 3 to 10 carbon atoms having single or multiple condensed rings.
  • cycloalkyl groups include C 4 -C 7 or C 3 -C 4 cyclic alkyl groups.
  • Non-limiting examples of cycloalkyl groups include adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
  • alkyl and cycloalkyl groups described herein can be unsubstituted or substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, alkyl- or dialkylamino, amido, arylamino, alkoxy, aryloxy, nitro, cyano, azido, thiol, imino, sulfonic acid, sulfate, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, phosphonic acid, phosphate, phosphonate, or any other viable functional group that does not inhibit the biological activity of
  • alkenyl refers to both straight and branched carbon chains which have at least one carbon-carbon double bond.
  • alkenyl groups may include C2-C20 alkenyl groups.
  • alkenyl includes C 2 -C 12 , C 2 -C 1 O, C 2 -Cs, C 2 -C 6 or C 2 -C 4 alkenyl groups.
  • the number of double bonds is 1-3, in another embodiment of alkenyl, the number of double bonds is one or two. Other ranges of carbon-carbon double bonds and carbon numbers are also contemplated depending on the location of the alkenyl moiety on the molecule.
  • C 2 -Cio-alkenyl groups may include more than one double bond in the chain. Examples include, but are not limited to, ethenyl, 1- propenyl, 2-propenyl, 1-methyl-ethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1 -methyl- 1- propenyl, 2-methyl-l-propenyl, l-methyl-2-propenyl, 2-methyl-2-propenyl; 1-pentenyl, 2- pentenyl, 3-pentenyl, 4-pentenyl, 1 -methyl- 1-butenyl, 2-methyl- 1-butenyl, 3-methyl-l- butenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2- methyl-3-butenyl, 3-methyl-3-butenyl, l,l-dimethyl-2-propenyl, 1,2-dimethyl
  • Cycloalkenyl refers to monovalent cyclic alkenyl groups of from 4 to 10 carbon atoms, preferably 5 to 8 carbon atoms, having single or multiple condensed rings which condensed rings may or may not be cycloalkenyl provided that the point of attachment is to a cycloalkenyl ring atom.
  • Examples of cycloalkenyl groups include, by way of example, cyclopenten-4-yl, cyclooctene-5-yl and the like.
  • Alkenyl and cycloalkenyl groups may be unsubstituted or substituted with one or more substituents as described for alkyl above.
  • alkynyl refers to both straight and branched carbon chains which have at least one carbon-carbon triple bond.
  • the number of triple bonds is 1-3; in another embodiment of alkynyl, the number of triple bonds is one or two.
  • alkynyl groups include from C 2 -C 2O alkynyl groups.
  • alkynyl groups may include C 2 -Ci 2 , C 2 -CiO, C 2 -Cs, C 2 -C 6 or C 2 -C 4 alkynyl groups.
  • Other ranges of carbon-carbon triple bonds and carbon numbers are also contemplated depending on the location of the alkenyl moiety on the molecule.
  • C 2 -Ci O - alkynyl refers to a straight-chain or branched unsaturated hydrocarbon group having 2 to 10 carbon atoms and containing at least one triple bond, such as ethynyl, prop-1- yn-l-yl, prop-2-yn-l-yl, n-but-1-yn-l-yl, n-but-l-yn-3-yl, n-but-l-yn-4-yl, n-but-2-yn-l-yl, n- pent-1-yn-l-yl, n-pent-l-yn-3-yl, n-pent-l-yn-4-yl, n-pent-l-yn-5-yl, n-pent-2-yn-l-yl, n- pent-2-yn-4-yl, n-pent-2-yn-5-yl, n-pent-2-yn-l-y
  • haloalkyl refers to an alkyl group, as defined herein, which is substituted by one or more halogen atoms.
  • Ci-C 4 -haloalkyl includes, but is not limited to, chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloro fluoromethyl, dichloro fluoromethyl, chlorodifluoromethyl, 1- chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2- trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl and the like.
  • fluoroalkyl refers to an alkyl in which one or more of the hydrogen atoms is replaced with fluorine atoms, for example difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 1,1,2,2-tetrafluoroethyl or pentafluoroethyl .
  • haloalkenyl refers to an alkenyl group, as defined herein, which is substituted by one or more halogen atoms.
  • haloalkynyl refers to an alkynyl group, as defined herein, which is substituted by one or more halogen atoms.
  • Alkoxy refers to alkyl-O-, wherein alkyl is as defined above.
  • alkenyloxy refers to alkyl-O-, wherein alkyl is as defined above.
  • alkenyloxy refers to the groups alkenyl-O-, alkynyl-O-, haloalkyl-O-, haloalkenyl-O-, haloalkynyl-O-, cycloalkyl- O-, cycloalkenyl-O-, halocycloalkyl-O-, and halocycloalkenyl-O-, respectively, wherein alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl-, respectively, wherein alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, respectively,
  • Ci-C ⁇ -alkoxy examples include, but are not limited to, methoxy, ethoxy, C 2 Hs-CH 2 O-, (CHs) 2 CHO-, n-butoxy, C 2 Hs- CH(CH 3 )O-, (CHs) 2 CH-CH 2 O- , (CH 3 ) 3 CO-, n-pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3- methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethyl-propoxy, 1- ethylpropoxy, n-hexoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, A- methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2- dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy
  • Aryl refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring or multiple condensed rings.
  • aryl groups include C 6 -Ci O aryl groups.
  • Aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, tetrahydronaphtyl, phenylcyclopropyl and indanyl.
  • Aryl groups may be unsubstituted or substituted by one or more moieties selected from halogen, cyano, nitro, hydroxy, mercapto, amino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, halocycloalkenyl, alkoxy, alkenyloxy, alkynyloxy, haloalkoxy, haloalkenyloxy, haloalkynyloxy, cycloalkoxy, cycloalkenyloxy, halocycloalkoxy, halocycloalkenyloxy, alkylthio, haloalkylthio, cycloalkylthio, halocycloalkylthio, alkylsulfinyl, alkenylsulfinyl, alky
  • aralkyl refers to an aryl group that is bonded to the parent compound through a diradical alkylene bridge, (-CH2-) n , where n is 1-12 and where "aryl” is as defined above.
  • Heteroaryl refers to a monovalent aromatic group of from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, having one or more oxygen, nitrogen, and sulfur heteroatoms within the ring, preferably 1 to 4 heteroatoms, or 1 to 3 heteroatoms. The nitrogen and sulfur heteroatoms may optionally be oxidized.
  • heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings provided that the point of attachment is through a heteroaryl ring atom.
  • Preferred heteroaryls include pyridyl, piridazinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, indolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinnyl, furanyl, thiophenyl, furyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyrazolyl benzofuranyl, and benzo thiophenyl.
  • Heteroaryl rings may be unsubstituted or substituted by one or more moieties as described for aryl above.
  • "Heterocyclyl,” “heterocyclic” or “heterocyclo” refer to fully saturated or unsaturated, cyclic groups, for example, 3 to 7 membered monocyclic or 4 to 7 membered monocyclic; 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring systems, which have one or more oxygen, sulfur or nitrogen heteroatoms in ring, preferably 1 to 4 or 1 to 3 heteroatoms.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized and the nitrogen heteroatoms may optionally be quaternized.
  • the heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system and may be unsubstituted or substituted by one or more moieties as described for aryl groups above.
  • Exemplary monocyclic heterocyclic groups include, but are not limited to, pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2- oxoazepinyl, azepinyl, 4-piperidonyl, pyridinyl, pyrazinyl, pyrimi
  • bicyclic heterocyclic groups include, but are not limited to, indolyl, benzothiazolyl, benzoxazolyl, benzodioxolyl, benzothienyl, quinuclidinyl, quinolinyl, tetra- hydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl]or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-qui
  • Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl, and the like.
  • Halogen means the atoms fluorine, chlorine, bromine and iodine.
  • the designation of "halo" (e.g. as illustrated in the term haloalkyl) refers to all degrees of substitutions from a single substitution to a perhalo substitution (e.g. as illustrated with methyl as chloromethyl (- CH 2 Cl), dichloromethyl (-CHCl 2 ), trichloromethyl (-CCl 3 )).
  • the compounds within the compositions of the invention may exist and be isolated as optically active and racemic forms.
  • Compounds having one or more chiral centers, including at a sulfur atom may be present as single enantiomers or diastereomers or as mixtures of enantiomers and/or diastereomers.
  • sulfoxide compounds may be optically active and may exist as single enantiomers or racemic mixtures.
  • compounds within the compositions of the invention may include one or more chiral centers, which results in a theoretical number of optically active isomers.
  • the compounds may comprise up to 2 n optical isomers.
  • the present invention encompasses the specific enantiomers or diastereomers of each compound as well as mixtures of different enantiomers and/or diastereomers of the compounds of the invention that possess the useful properties described herein.
  • the optically active forms can be prepared by, for example, resolution of the racemic forms by selective crystallization techniques, by synthesis from optically active precursors, by chiral synthesis, by chromatographic separation using a chiral stationary phase or by enzymatic resolution.
  • compositions of present invention may also be present in different solid forms such as different crystalline forms or in the form of an amorphous solid.
  • present invention encompasses different crystalline forms as well as amorphous forms of the inventive compounds.
  • compositions of the invention may exist as hydrates or solvates, in which a certain stoichiometric amount of water or a solvent is associated with the molecule in the crystalline form.
  • hydrates and solvates of the compounds of formula (I) or (II) are also the subject of the invention. Salts
  • acid or base salts contemplated within the scope of the invention.
  • the term "acid” contemplates all pharmaceutically acceptable inorganic or organic acids.
  • Inorganic acids include mineral acids such as hydrohalic acids such as hydrobromic acid and hydrochloric acid, sulfuric acid, phosphoric acids and nitric acid.
  • Organic acids include all pharmaceutically acceptable aliphatic, alicyclic and aromatic carboxylic acids, dicarboxylic acids, tricarboxylic acids and fatty acids.
  • the acids are straight chain or branched, saturated or unsaturated C 1 -C 20 aliphatic carboxylic acids, which are optionally substituted by halogen or by hydroxyl groups, or C 6 -Ci 2 aromatic carboxylic acids.
  • examples of such acids are carbonic acid, formic acid, acetic acid, propionic acid, isopropionic acid, valeric acid, ⁇ -hydroxy acids such as glycolic acid and lactic acid, chloroacetic acid, benzoic acid, methane sulfonic acid, and salicylic acid.
  • dicarboxylic acids include oxalic acid, malic acid, succinic acid, tartaric acid, fumaric acid, and maleic acid.
  • a tricarboxylic acid is citric acid.
  • Fatty acids include all pharmaceutically or veterinarily acceptable saturated or unsaturated aliphatic or aromatic carboxylic acids having 4 to 24 carbon atoms. Examples include butyric acid, isobutyric acid, sec-butyric acid, lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and phenylsteric acid.
  • Other acids include gluconic acid, glycoheptonic acid and lactobionic acid.
  • base contemplates all pharmaceutically or veterinarily acceptable inorganic or organic bases, including hydroxides, carbonates or bicarbonates of alkali metal or alkaline earth metals. Salts formed with such bases include, for example, the alkali metal and alkaline earth metal salts, including, but not limited to, as the lithium, sodium, potassium, magnesium or calcium salts. Salts formed with organic bases include the common hydrocarbon and heterocyclic amine salts, which include, for example, ammonium salts (NH4 + ), alkyl- and dialkylammonium salts, and salts of cyclic amines such as the morpholine and piperidine salts.
  • a first aspect of the invention provides a formulation with increased stability and/or efficacy for treating or preventing an infestation of an animal with ectoparasites and/or endoparasites comprising:
  • R 2 is R 8 , halogen, cyano, nitro, -SCN, 4-5-dicyanoimidazol-2-yl, or -S(0) m Rn;
  • R 3 is alkyl, haloalkyl, OH, or NR 9 Ri 0 ;
  • R 4 , R 5 and R 7 are independently hydrogen, halogen, alkyl, haloalkyl, cyano or nitro;
  • Re is halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy, cyano, nitro, -C(O)Ri 2 , -
  • Z is a nitrogen atom or C-Ri 3 ;
  • R 8 is alkyl, haloalkyl, cycloalkyl or halocycloalkyl;
  • R 9 is hydrogen, alkyl, haloalkyl or alkoxy;
  • Rio is hydrogen, alkyl, haloalkyl, alkoxy, or -C(O)R 8 ; wherein said alkyl, haloalkyl, alkoxy, or -C(O)R 8 groups are optionally substituted with alkyl, haloalkyl, cycloalkyl, alkoxy, aryl, or heteroaryl; wherein said aryl or heteroaryl groups are optionally substituted with one or more groups selected from the group consisting of alkyl, cycloalkyl, haloalkyl, aryl, halogen, C(O)R 8 , -C(O)OR 8 , -C(O)NR 9 R 9 , -C(
  • Ri 2 is alkyl or haloalkyl
  • Ri 3 is hydrogen, halogen, cyano, nitro, alkyl, haloalkyl, alkoxy or haloalkoxy; m is 0, 1 or 2; and n is 0, 1 or 2; or a salt thereof;
  • the pharmaceutically or veterinarily acceptable carrier comprises acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate (also known as CERAPHYL 230), butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone including N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, amides including dimethylformamide and dimethylacetamide, or any combination thereof.
  • the pharmaceutically or veterinarily acceptable carrier of the formulation includes C 1 -C 1O alcohols or esters thereof (including acetates, such as ethyl acetate, butyl acetate and the like), C 1O -C 18 saturated fatty acids or esters thereof, C 1O -C 18 monounsaturated fatty acids or esters thereof, monoesters or diesters of aliphatic diacids, glycerol monoesters (e.g. monoglycerides), glycerol diesters (e.g. diglycerides), glycerol triesters (e.g.
  • triglycerides such as triacetin
  • glycols such as triacetin
  • glycol ethers such as glycol esters or glycol carbonates
  • PEGs polyethylene glycols of various grades
  • monoethers such as diethers, monoesters or diesters thereof (e.g. diethylene glycol monoethyl ether), or mixtures thereof.
  • the carrier may include diisopropyl adipate, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, 2-pyrrolidone including N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, oleic acid, or a mixture of at least two of these solvents.
  • the carrier may include triacetin or diethylene glycol monoethyl ether.
  • the invention may also be effective against endoparasites, cestodes, nematodes, such as filariae, and roundworms of the digestive tract of animals and humans.
  • the pharmaceutically or veterinarily acceptable carrier is an organic solvent commonly used in the formulation art. These organic solvents may be found, for example, in Remington Pharmaceutical Sciences, 16 th Edition
  • solvents include, for example, acetone, ethyl acetate, methanol, ethanol, isopropanol, dimethylformamide, dichloromethane or diethylene glycol monoethyl ether
  • Cio alcohols C 1O -C 18 monounsaturated fatty acids or esters thereof, propylene carbonate, butylene carbonate, or any combination thereof.
  • These solvents can be supplemented by various excipients according to the nature of the desired phases, such as C 8 -Ci 0 caprylic/capric triglyceride (ESTASAN or MIGLYOL 812), oleic acid or propylene glycol.
  • the invention provides a formulation comprising a 1- arylpyrazole of formula (I) wherein R 3 is alkyl or haloalkyl.
  • the invention provides a formulation comprising a 1-arylpyrazole of formula (I) wherein:
  • R 2 is -SCN, 4-5-dicyanoimidazol-2-yl, or -S(O) 1n R 11 .
  • the invention provides a formulation comprising a 1- arylpyrazole of formula (I) wherein:
  • R 2 is -SCN, 4-5-dicyanoimidazol-2-yl, or -S(O) 1n R 11 ;
  • R 3 is alkyl or haloalkyl.
  • the invention provides a formulation comprising a 1- arylpyrazole of formula (I) wherein: Ri is cyano;
  • R 2 is -SCN, 4-5-dicyanoimidazol-2-yl, or -S(O) 1n R 11 ;
  • R 3 is alkyl or haloalkyl
  • R 4 , R 5 and R 7 are independently hydrogen, or halogen; and Z is C-R 13 .
  • the invention provides a formulation comprising a 1- arylpyrazole of formula (I) wherein:
  • Ri is cyano
  • R 2 is -SCN, 4-5-dicyanoimidazol-2-yl, or -S(O) 1n R 11 ;
  • R 3 is C r C 4 alkyl or C r C 4 haloalkyl;
  • Re is halogen, haloalkyl or SF 5 ;
  • the invention provides a formulation comprising a 1-arylpyrazole of formula (I) wherein: Ri is cyano;
  • R 2 is -S(O) 1n R 11 ;
  • R 3 is C r C 4 alkyl, C r C 4 haloalkyl, or NR 9 Ri 0 ;
  • R 4 , R 5 and R 7 are independently hydrogen, or halogen
  • Re is halogen, Ci-C 4 alkyl, Ci-C 4 haloalkyl, or SF 5 ;
  • Rn is halogen or Ci-C 4 haloalkyl.
  • Ri is cyano;
  • R 2 is -S(O) 1n R 11 ;
  • R 3 is methyl, ethyl, propyl, or Ci-C 4 haloalkyl
  • R 4 is halogen
  • R 5 and R 7 are hydrogen
  • R 6 is C r C 4 haloalkyl
  • Rn is -CF 3 , -CClF 2 , or CFCl 2 ;
  • Ri 3 is halogen
  • the invention provides a formulation comprising a 1- arylpyrazole of formula (I) wherein: Ri is cyano; ;
  • R 3 is methyl or ethyl
  • R 4 is chloro or fluoro
  • R 5 and R 7 are hydrogen
  • R 6 is -CF 3 ;
  • Rn is -CFCl 2 ;
  • Ri 3 is chloro or fluoro.
  • the invention provides a formulation comprising a 1-aryl- alkyl or 5-haloalkylpyrazole of formula (I) that has the structure of formula (IA) below in combination with a veterinarily acceptable carrier and optionally a crystallization inhibitor:
  • R 3a is methyl, ethyl or C 1 -C 4 haloalkyl
  • R 4a is halogen
  • R 6a is Ci -C 4 alkyl or haloalkyl
  • Ri 3a is halogen
  • Riia is Ci-C 4 haloalkyl; and m is 0, 1 or 2.
  • the invention provides a formulation that comprises a 1-aryl- 5-alkyl pyrazole compound of formula (IA) wherein: R 3a is methyl, or ethyl; R 4a is halogen; R 6a is Ci-C 4 haloalkyl; Ro a is halogen;
  • Rii a is -CF 3 , -CClF 2 , or -CFCl 2 ; and m is 0, 1 or 2.
  • the invention provides a formulation that comprises a 1-aryl- 5-alkyl pyrazole compound of formula (IA) wherein:
  • R 3a is methyl, or ethyl; R 4a is halogen; R ⁇ a is Ci-C 4 haloalkyl; Ri 3a is halogen; Riia is -CF 3 , -CClF 2 , or -CFCl 2 ; and m is 0, 1 or 2.
  • a formulation comprising a l-aryl-5-alkyl pyrazole compound of formula (IA) wherein: R 3a is methyl;
  • R 4a is -Cl; R 6a is -CF 3 ; Ri 3a is -F; m is 0, 1 or 2.
  • the invention provides a formulation comprising 3-cyano-l- (2-chloro-6-fluoro-4-trifluoromethylphenyl)-4-dichlorofluoromethylsulfinyl-5-methyl-lH- pyrazole (Compound 1) in combination with a pharmaceutically or veterinarily acceptable carrier and optionally a crystallization inhibitor. It has been surprisingly discovered that l-aryl-5-alkyl or 5-haloalkyl pyrazole compounds are highly efficacious against ectoparasites and provide long-lasting protection against ectoparasites for at leat 30, at least 40 or at least 60 days.
  • l-aryl-5-alkyl or 5- haloalkyl pyrazoles of formula (IA) are extremely useful and offer substantial advantages to other paraciticidal compounds. Furthermore, it has been discovered that l-aryl-5-alkyl or 5- haloalkyl pyrazole compounds of formula (IA) are able to eradicate parasites, particularly fleas and ticks, from animals more quickly than other parasiticides.
  • a third aspect of the invention provides a composition comprising one or more formamidine compounds including, but not limited to amitraz, that exhibits enhanced stability.
  • the formamidine compositions of the invention typically comprise amitraz in combination with an aprotic solvent.
  • the compositions comprise a veterinarily effective amount of a formamidine in combination with a polar aprotic solvent.
  • Aprotic solvents and polar aprotic solvents are well known in the art, and the invention provides compositions comprising any veterinarily acceptable aprotic or polar aprotic solvent that provides sufficient solubility for the formamidine compound may be used.
  • Particularly preferred polar aprotic solvents include carboxylic acid esters, ketones and aryl ethers.
  • the stable formamidine compositions of the invention comprise a veterinarily effective amount of one or more formamidine compounds and solvent with a dielectric constant of about 2 to about 30.
  • the stable formamidine compositions of the invention comprise aprotic solvents that have a dielectric constant of about 2 to about 30.
  • the stable formamidine compositions comprise polar aprotic solvents that have a dielectric constant of about 2 to about 30.
  • the carrier comprises a solvent with a dielectric constant of about 2 to about 40, 2 to about 20, 5 to about 30, or 10 to about 30.
  • the solvent with dielectric constants of about 2 to about 40 is an aprotic solvent or a polar aprotic solvent.
  • the carrier comprises one or more solvents with a dielectric constant of about 2 to about 15 or about 3 to about 10. In still another embodiment, the dielectric constant of the one or more solvents is about 3.5 to about 10. In another embodiment, the dielectric constant of the one or more solvents is about 4 to about 6.5.
  • the carrier comprises one or more aprotic solvents with dielectric constants of about 2 to about 40, 2 to about 20, 5 to about 30, or 10 to about 30. In other embodiments, the carrier comprises one or more aprotic solvents with dielectric constants of about 2 to about 15 or about 3 to about 10. In still another embodiment, the dielectric constant of the one or more aprotic solvents is about 3.5 to about
  • the dielectric constant of the one or more aprotic solvents is about 4 to about 6.5.
  • the carrier comprises one or more polar aprotic solvents with dielectric constants of about 2 to about 40, 2 to about 20, 5 to about 30, or 10 to about 30.
  • the carrier comprises one or more polar aprotic solvents with dielectric constants of about 2 to about 15 or about 3 to about 10. In still another embodiment, the dielectric constant of the one or more polar aprotic solvents is about 3.5 to about 10. In another embodiment, the dielectric constant of the one or more polar aprotic solvents is about 4 to about 6.5.
  • the carrier comprises a single solvent with a dielectric constant of about 2 to about 30. In still another embodiment, the carrier comprises a mixture of two or more solvents with a dielectric constant of about 2 to about 30, which may preferably be aprotic or polar aprotic.
  • the carrier comprises a solvent with a dielectric constant of about 2 to about 30 in combination with one or more solvents that do not have a dielectric constant of about 2 to about 30.
  • the solvent in the stable formamidine compositions will contain less than about 0.5% or less than about 0.3% (w/w) water. In other embodiments, the solvent will typically contain less than 0.2% (w/w) water. Preferably, the solvent will contain less than about 0.1%, or less than about 0.05% or less than about 0.025% (w/w) water. In other embodiments, the solvent will contain from about 0.0001% (w/w) to about 0.5% (w/w) water. More typically, the solvent will contain about 0.0001% to about 0.3%, about 0.001% to about 0.3%, about 0.001% to about 0.1% or about 0.001% to about 0.05% (w/w) water.
  • the solvent will contain from about 0.001% to about 0.025% (w/w) water.
  • amitraz has been shown to be unstable in aqueous solutions at certain pH ranges or solutions containing significant amounts of water at certain pH ranges.
  • formamidine compounds, and amitraz in particular may not have sufficient long term stability in certain solvent systems.
  • amitraz may not provide a sufficient shelf life for use as a commercial veterinary pharmaceutical product. Therefore, compositions of formamidines in certain carriers that exhibit enhanced stability are highly desired.
  • the invention provides a composition comprising a formamidine, including amitraz, in combination with a suitable carrier that is stable for up to about 2 months at about 50 0 C.
  • a stable composition comprising a formamidine, as described herein will show less than about 5 % degradation of the formamidine compound at the indicated conditions (temperature and relative humidity) relative to the initial measure of purity or concentration, as tested by a suitable stability-indicating method for a given period of time.
  • the stability of a formulation is evaluated by HPLC by measuring the change in concentration of the active in the formulation over time against a reference standard.
  • the invention provides a composition comprising a formamidine, including amitraz, that is stable for at least about 3 months at about 50° C. In still other embodiments, the invention provides a composition comprising a formamidine, including amitraz, that is stable for at least about 4 months, at least about 5 months or at least about 6 months at about 50° C.
  • the invention provides a composition comprising a formamidine compound, including amitraz, that is stable for at least 3 months at about 40° C and about 75% relative humidity (RH).
  • the composition comprising a formamidine compound will be stable for at least 6 months at about 40° C and 75% RH.
  • the composition comprising a formamidine will be stable for at least 9 months at about 40° C and 75% RH.
  • the invention provides a composition comprising a formamidine, including amitraz, that is stable for at least about 12 months at about 25° C and about 60% RH. In other embodiments, the invention provides a composition comprising a formamidine, including amitraz, that is stable for at least about 18 months, about 24 months or about 36 months at about 25° C and about 60% RH.
  • the invention provides stable compositions comprising a formamidine in combination with one or more of amides including dimethylformamide, dimethylacetamide, N-methylpyrrolidone and the like; one or more sulfoxides including dimethyl sulfoxide and the like; and combinations thereof.
  • the solvent includes aryl ethers including alkoxybenzene compounds; carboxylic acid esters, including aliphatic and aromatic carboxylic acids such as benzoic acid esters, and compounds with multiple carboxylate groups; aliphatic ketones, saturated aliphatic ketones, cyclic ketones, or mixtures thereof.
  • the solvent includes C 1 -C 1O carboxylic acid esters, phenyl carboxylic acid esters, carboxylic acid benzyl esters, benzoic acid C 1 -C 4 alkyl esters, Ci-C 6 saturated aliphatic ketones, and mixtures thereof.
  • carboxylic acid esters include, but are not limited to C 1 -C 2O alkyl esters of alkanoic acids.
  • the solvent includes C 1 -C 20 alkyl esters of C 1 -C 12 alkanoic acids.
  • the solvent includes C 1 -C 12 alkyl esters of C 1 -C 12 alkanoic acids, C 1 -C 12 alkyl esters of C 1 -C 1O alkanoic acids, C 1 -C 12 alkyl esters of C 1 -C 8 alkanoic acids, C 1 -C 12 alkyl esters of Ci-C 6 alkanoic acids or C 1 -C 12 alkyl esters of C 1 - C 4 alkanoic acids.
  • the solvent includes C 1 -C 12 alkyl esters of formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, isobutanoic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, and the like.
  • phenyl and benzyl esters of alkyl carboxylic acids are also encompassed by the invention.
  • Other carboxylic acid esters include C 1 -C 20 alkyl esters of di-carboxylic and tricarboxylic acids including, but not limited to, malonic acid, succinic acid, glutaric acid, adipic acid, citric acid, and the like.
  • Aromatic carboxylic acid esters are also contemplated, including C 1 -C 20 alkyl esters of aromatic carboxylic acids as well as well as benzyl esters of aromatic carboxylic acids.
  • Non-limiting examples of aromatic carboxylic acids include, but are not limited to, benzoic acid, phenylacetic acid, salicylic acid, mandelic acid, phthalic acid, cynnamic acid, and the like.
  • Aliphatic ketones that may be used as solvents for veterinary formulations are well known in the art and include, but are not limited to, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl isopropyl ketone, 2-butanone, 2-pentanone, 3-pentanone, 2- hexanone, 3-hexanone, and the like.
  • Aryl ethers that may be used include, but are not limited to, C 1 -C 12 alkyl-aryl ethers such as anisole and derivatives of anisole, ethyl phenyl ether (phenetole), propyl phenyl ether, butyl phenyl ether, and the like.
  • the solvent of the stable formamidine compositions includes Ci-C 4 -alkoxybenzene, C 1 -C 1O carboxylic acid esters, phenyl carboxylic acid esters, carboxylic acid benzyl esters, Ci-C 6 saturated aliphatic ketones, benzoic acid C 1 -C 4 esters or mixtures thereof.
  • the solvent includes methoxybenzene (4.33), butyl acetate (5.0), benzyl acetate (5.0), methyl isobutyl ketone (13.1), ethyl benzoate (6.02), benzyl benzoate (4.8), octyl acetate or mixtures thereof. (Dielectric constants in parentheses)
  • the solvent is a mixture of butyl acetate and anisole or a mixture of butyl acetate and methyl isobutyl ketone.
  • the solvent is octyl acetate.
  • the carrier comprises a mixture of octyl acetate with another aprotic solvent or with a solvent having a dielectric constant of about 2 to about 30.
  • the solvent will be a polar aprotic solvent with a dielectric constant of about 2 to about 30.
  • the carrier comprises a mixture of octyl acetate with one or more of butyl acetate, methyl isobutyl ketone or anisole.
  • the [weight/volume] % solubility of amitraz at room temperature in the solvent is from about 20% to about 50%. In another embodiment, the [weight/volume] % solubility of amitraz at room temperature is from about 24% to about 46%. In still other embodiments, the [weight/volume] % solubility of amitraz at room temperature in the solvent is from about 10% to about 60%, about 20% to about 60%, or about 10% to about 50%.
  • a fourth aspect of the invention provides a formamidine composition (e.g.
  • enhanced odor dissipation refers to the faster dissipation of the initial odor exhibited by the formulation within a period of time compared to the time required for dissipation of odor by formulations of the prior art.
  • the odor dissipation occurs within about 5 to about 25 minutes.
  • the odor dissipation occurs within about 10 to about 15 minutes. In still another embodiment, the odor dissipation occurs within about 5 minutes to about 15 minutes, within about 10 minutes to about 25 minutes or within 15 minutes to about 25 minutes. In comparison, formamidine formulations of the prior art exhibit an odor that does not dissipate within 25 minutes.
  • the formamidine composition with enhanced odor dissipation properties comprises one or more solvents with dielectric constants of about 2 to about 20, about 5 to about 30, or aboutlO to about 30. More typically, the dielectric constant of the one or more solvents will be between about 2 to about 15 or about 2 to about 10.
  • the formamidine composition with enhanced odor dissipation properties comprises one or more aprotic solvents, preferably one or more polar aprotic solvents, with dielectric constants of about 2 to about 20, about 5 to about 30, or aboutlO to about 30. More typically, the dielectric constant of the one or more polar aprotic solvents will be between about 2 to about 15 or about 2 to about 10.
  • the one or at least two solvents that improve the odor dissipation of formamidine compositions include, but are not limited to, an alkoxybenzene, carboxylic acid esters, aliphatic ketones, saturated aliphatic ketones, benzoic acid esters or mixtures thereof.
  • the one or more solvents that improve the odor dissipation of formamidine compositions include, but are not limited to, aryl ethers including alkoxybenzene compounds; carboxylic acid esters, including esters of aliphatic and aromatic carboxylic acids such as benzoic acid esters, and compounds with multiple carboxylate groups; aliphatic ketones, cyclic ketones, or mixtures thereof.
  • the one or at least two solvents that improve the odor dissipation of formamidine compositions include Ci-C 4 -alkoxybenzene, C 1 -C 1O carboxylic acid esters, phenyl carboxylic acid esters, carboxylic acid benzyl esters, carboxylic acid phenyl esters, benzyl carboxylic acid esters, Ci-C 6 saturated aliphatic ketones, C 1 -C 4 benzoic acid esters and mixtures thereof.
  • the formamidine compositions with improved odor dissipation comprise one or at least two aprotic solvents each with a dielectric constant of about 2 to about 15 including, but not limited to, methoxybenzene (4.33), butyl acetate (5.0), benzyl acetate (5.0), methyl isobutyl ketone (13.1), ethyl benzoate (6.02), benzyl benzoate (4.8), octyl acetate and mixtures thereof, (dielectric constants in parentheses)
  • the dielectric constant of the one or more solvents is about 3 to about 10, about 3.5 to about 10, or about 4 to about 6.5.
  • the solvent is octyl acetate.
  • the at least two solvents in the formamidine compositions with improved odor dissipation is a mixture of butyl acetate and anisole or a mixture of butyl acetate and methyl isobutyl ketone.
  • a fifth aspect of the invention provides a composition for the treatment and/or prevention of a parasitic infestation in an animal comprising at least one (i.e.
  • the one or more 1-arylpyrazole compound(s) are in a first carrier and the formamidine compound(s) are in a second carrier, wherein the compounds and the first and second carrriers are compartmentalized separately from each other and are not in fluid communication before administration.
  • the one or more 1- arylpyrazole compound(s) and the formamidine compound(s) are in one common carrier.
  • first carrier and the second carrier may be the same or different.
  • first and second carriers may comprise the same solvent or may include different solvents or combinations of solvents.
  • the composition comprises:
  • Ri b is alkyl, CN or halogen
  • R 2 b is S(O) n Ri4b or 4,5-dicyanoimidazol-2-yl or haloalkyl;
  • Ri 4b is alkyl or haloalkyl
  • R ⁇ b is a halogen, haloalkyl, haloalkoxy, S(CO q CF 3 or SF 5 group;
  • R 7B and Rg B independently represent a hydrogen, alkyl, haloalkyl, -C(O)alkyl, -S(O) 1 CF 3 , acyl or alkoxycarbonyl; or
  • R 7b and R 8b can together form a divalent alkylene radical which is optionally interrupted by one or two divalent heteroatoms;
  • R 9b is an alkyl or haloalkyl
  • Rio b is hydrogen, alkyl or haloalkyl
  • Ru b is hydrogen or alkyl radical
  • Ri 2b is an optionally substituted aryl or an optionally substituted heteroaryl group
  • R 4 b and Ri 3 b represent, independently of one another, hydrogen, halogen CN or NO 2 ; m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2; Z represents a trivalent nitrogen atom or a C-Ri 3b radical, the three other valencies of the carbon atom forming part of the aromatic ring; and
  • At least one formamidine compound comprises at least one compound of formula (II):
  • x is an integer from 0-5;
  • Ri 5 is hydrogen or alkyl
  • Ri6 is hydrogen or alkyl
  • Rn is hydrogen, alkyl or
  • the 1-arylpyrazole (s) is a compound of formula (IB), wherein
  • Ri b is methyl, CN or halogen
  • Ri 4b is Ci-C ⁇ -alkyl or Ci-C ⁇ -haloalkyl
  • R 7b and R 8b independently represent a hydrogen, Ci-C ⁇ -alkyl, Ci-C ⁇ -haloalkyl, - C(O)Ci-C 6 -alkyl, -S(O) 1 CF 3 , Ci-C 6 -acyl or Ci-C 6 -alkoxycarbonyl radical; or
  • R 7b and R 8b may together form a divalent alkylene radical which may be interrupted by one or two divalent hetero atoms selected from the group consisting of oxygen or sulfur;
  • R % is a Ci-C ⁇ -alkyl or Ci-C ⁇ -haloalkyl radical;
  • Rio b is a Ci-C ⁇ -alkyl or Ci-C ⁇ -haloalkyl radical or a hydrogen atom;
  • Ru b is a Ci-C ⁇ -alkyl radical or a hydrogen atom;
  • Ri 2b is an optionally substituted phenyl or optionally substituted heteroaryl group wherein the substituents are selected from the group consisting of halogen, -OH, -0-C 1 -C 6 - alkyl, -S-C r C 6 -alkyl, cyano and C r C 6 -alkyl;
  • R ⁇ b is a halogen, Ci-C ⁇ -haloalkyl, Ci-C ⁇ -haloalkoxy, S(O) q CF 3 or SF 5 group; and Z is a C-Ri3b radical.
  • the l-arylpyrazole(s) is a compound of formula (IB), wherein
  • Ri b is methyl, CN or halogen
  • Ri 4b is Ci-C ⁇ -alkyl or Ci-C ⁇ -haloalkyl; R 7b and R 8b independently represent a hydrogen, Ci-C ⁇ -alkyl, Ci-C ⁇ -haloalkyl, -
  • the l-arylpyrazole(s) is a compound of formula (IB), wherein Rib is CN; Ri4b is CF 3 ; R 3b is NR 7b R 8b ;
  • R 7b and R 8b are hydrogen; R4b and Ri 3 b are each Cl; R 6 b is CF 3 .
  • this compound is also known as fipronil or l-[2,6-dichloro-4-trifluoromethylphenyl]- 3-cyano-4-trifluoromethylsulfinyl-5-amino pyrazole).
  • the formulation comprises at least one formamidine compound and at least one 1-arylpyrazole of formula (I) as described above, one or more pharmaceutically acceptable carrier(s), and optionally one or more crystallization inhibitors.
  • the formulation comprises at least one formamidine compound of formula (II) described above and at least one 1- arylpyrazole compound of formula (I) described above, one or more pharmaceutically acceptable carrier(s), and optionally one or more crystallization inhibitors.
  • the l-arylpyrazole(s) of formula (I) is provided wherein R 3 is alkyl or haloalkyl.
  • the formulation comprises a 1- arylpyrazole(s) of formula (I) wherein:
  • R 2 is -SCN, 4-5-dicyanoimidazol-2-yl, or -S(0) m Rn.
  • the l-arylpyrazole(s) of formula (I) is provided wherein:
  • R 2 is -SCN, 4-5-dicyanoimidazol-2-yl, or -S(0) m Rn; and R 3 is alkyl or haloalkyl.
  • Ri is cyano
  • R 2 is -SCN, 4-5-dicyanoimidazol-2-yl, or -S(0) m Rn;
  • R 3 is alkyl or haloalkyl;
  • R 4 , R 5 and R 7 are independently hydrogen, or halogen
  • the formulation comprises at least one l-arylpyrazole(s) of formula (I) is provided wherein: Ri is cyano;
  • R 2 is -SCN, 4-5-dicyanoimidazol-2-yl, or -S(0) m Rn;
  • R 3 is Ci-C 4 alkyl or Ci-C 4 haloalkyl
  • the formulation comprises at least one l-arylpyrazole(s) of formula (I) wherein:
  • Ri is cyano
  • R 2 is -S(O) 1n R 11 ;
  • R 3 is C r C 4 alkyl, C r C 4 haloalkyl, or NR 9 Ri 0 ;
  • R 4 , R 5 and R 7 are independently hydrogen, or halogen
  • R 6 is halogen, Ci-C 4 alkyl, Ci-C 4 haloalkyl, or SF 5 ;
  • Rn is halogen or Ci-C 4 haloalkyl.
  • the formulation comprises at least one 1-arylpyrazole of formula (I) wherein:
  • Ri is cyano
  • R 3 is methyl, ethyl, propyl, or Ci-C 4 haloalkyl; R 4 is halogen;
  • R 5 and R 7 are hydrogen
  • R 6 is C r C 4 haloalkyl
  • Rn is -CF 3 , -CClF 2 , or CFCl 2 ; and Ri 3 is halogen.
  • the formulation comprises at least one 1-arylpyrazole of formula (I) wherein:
  • Ri is cyano
  • R 2 is -S(O) 1n R 11 ;
  • R 3 is methyl or ethyl;
  • R 4 is chloro or fluoro
  • R 5 and R 7 are hydrogen
  • R 6 is -CF 3 ;
  • Rn is -CFCl 2 ;
  • Ri 3 is chloro or fluoro.
  • the formulation comprising at least one 1-arylpyrazole and at least one formamidine compound comprises at least one 1- arylpyrazole of formula (IA) as described above, or a salt thereof, a pharmaceutically or veterinarily acceptable carrier, and optionally at least one crystallization inhibitor.
  • the formulation comprises at least one formamidine of formula (II) described above and at least one 1-arylpyrazole compound of formula (IA) described above, or salts thereof, a pharmaceutically or veterinarily acceptable carrier, and optionally at least one crystallization inhibitor.
  • the formulation comprises at least one l-aryl-5-alkyl pyrazole compound of formula (IA) wherein:
  • R 2a is -S(O) 1n R 1 la ;
  • R 3a is methyl, or ethyl; R 4a is halogen;
  • R 6a is Ci-C 4 haloalkyl
  • Ri3a is halogen
  • Rii a is -CF 3 , -CClF 2 , or -CFCl 2 ; and m is 0, 1 or 2.
  • the formulation comprises at least one l-aryl-5-alkyl pyrazole compound of formula (IA) wherein:
  • R 3a is methyl, or ethyl
  • R 4a is halogen;
  • R 6a is Ci-C 4 haloalkyl;
  • Ri 3a is halogen
  • Rii a is -CF 3 , -CClF 2 , or -CFCl 2 ; and m is 0, 1 or 2.
  • the compound(s) of formula (IA) is a compound wherein:
  • R 3a is methyl
  • R 4a is -Cl
  • R 6a is -CF 3 ; Ri 3a is -F; m is 0, 1 or 2.
  • the formamidine compound(s) in the formulation is a compound of formula (II), wherein x is an integer from 1 to 3;
  • the formamidine compound(s) is a compound of formula (II), wherein x is an integer from 1 to 2;
  • the formamidine compound(s) is selected from the group consisting of:
  • the formamidine compound is:
  • the 1-arylpyrazole is fipronil and the formamidine compound is amitraz.
  • the 1- arylpyrazole compound(s) is in one carrier system and the formamidine compound(s) is in a separate second carrier system.
  • a sixth aspect of the invention provides composition for the treatment and prevention of parasites in an animal in need thereof which comprises:
  • x is an integer from 0-5;
  • Ri 6 is hydrogen or alkyl
  • Rn is hydrogen, alkyl or
  • Ri 4 is Ci-C 4 alkyl or halogen
  • Ri 5 is hydrogen or CrC 4 alkyl
  • Ri6 is hydrogen or CrGtalkyl.
  • the composition has enhanced odor dissipation following application or administration.
  • the composition has enhanced stability compared to compositions comprising formamidines of the prior art.
  • the composition comprises one or at least two aprotic solvents each with a dielectric constant of about 2 to about 30.
  • the composition comprises octyl acetate.
  • the composition comprises at least two solvents in a mixture of butyl acetate and anisole or a mixture of butyl acetate and methyl isobutyl ketone.
  • the formamidine compound (a) is amitraz.
  • a method for preventing or treating a parasite infestation/infection in an animal comprising administering a composition comprising an effective amount of at least one 1-arylpyrazole compound of formula (I), (IA) or (IB) together with a pharmaceutically or veterinarily acceptable carrier and optionally a crystallization inhibitor.
  • the compositions or formulations of the invention have long-lasting efficacy against fleas and ticks and are also able to quickly eradicate flea and tick infestations.
  • a formulation comprising a 1-arylpyrazole compound of formula (IA) has an efficacy of about 90% or greater against fleas 30 days after application. In another embodiment, a formulation comprising a 1-arylpyrazole compound of formula (IA) has an efficacy of about 99% or greater against fleas 51 days or 58 days after application.
  • a formulation comprising a 1-arylpyrazole compound of formula (IA) has an efficacy of about 85% or greater against ticks 23 days after application. In yet another embodiment, a formulation comprising a 1-arylpyrazole compound of formula (IA) has an efficacy of about 90% or greater against ticks 44 days or 58 days after application. In still another embodiment, a formulation comprising a 1-arylpyrazole compound of formula (IA) has an efficacy of about 99% or greater against ticks 58 days after application.
  • a formulation comprising a 1-arylpyrazole of formula (IA) is able to eradicate a flea infestation (as tested in the examples herein) more quickly than 1- arylpyrazole compounds of the prior art.
  • the 1-arylpyrazole compound is able to eradicate a flea infestation in less than 10 hours or less than 9 hours after application.
  • a formulation comprising a 1-arylpyrazole of formula (IA) is able to eradicate a tick infestation (as tested in the examples herein) in less than 20 hours after application.
  • the invention provides a method for preventing or treating an ectoparasitic infestation/infection in an animal. In another embodiment, the invention provides a method for preventing or treating an endoparasitic infestation/infection in an animal. In certain embodiments for treating an endoparasitic infestation, the compositions of the invention may include an additional anthelmintic agent.
  • the composition comprising the 1-arylpyrazole compound (s) and the carrier exhibits enhanced stability and/or enhanced efficacy.
  • An eighth aspect of the invention provides a method for treating or preventing a parasite infestation in an animal in need thereof comprising administering an effective amount of a composition of the invention that comprises at least one 1-arylpyrazole compound, at least one formamidine compound or at least one formamide compound, or combinations thereof, and optionally at least one crystallization inhibitor; wherein the 1- arylpyrazole is administered in a first carrier and the formamidine compound is administered in a second carrier, and wherein the first carrier is isolated from the second carrier and not in fluid communication with the second carrier within the administration device.
  • the 1-arylpyrazole compound (s) is a compound of formula (I), (IA) or (IB).
  • the formamidine compound (s) is a formamidine compound of formula (II).
  • the method of the invention encompasses administering the 1-arylpyrazole compound(s) separately from the formamidine compound as well as administering the 1-arylpyrazole compound(s) together with the formamidine compound(s), although the two compounds may be in separate carriers.
  • the 1-arylpyrazole compound(s) may be administered at the same location on the animal as the formamidine compound(s) or the 1-arylpyrazole compound(s) may be administered at a different location on the animal.
  • the 1-arylpyrazole compound(s) may be administered by one mode of administration (e.g. topical, oral, parenteral, etc.) while the formamidine compound(s) may be administered by a different mode of administration.
  • the method of the invention also encompasses the administration of the 1-arylpyrazole compound(s) simultaneously with the formamidine compound(s) or sequentially with the formamidine compound(s) (i.e. at different times).
  • the first carrier comprises a first solvent system and the second carrier comprises a second solvent system that is different from the first solvent system.
  • the method comprises administering the 1-arylpyrazole (s) separately from the formamidine compound(s). In another embodiment, the 1-arylpyrazole (s) is administered simultaneously with the formamidine compound(s).
  • the arylpyrazole(s) is administered separately and simultaneously with the formamidine compound(s).
  • a method for preventing or treating a parasite infestation in an animal comprising administering an effective amount of at least one 1-arylpyrazole compound and an effective amount of at least one formamidine or formamide compound to the animal in need thereof, wherein the compounds are administered via a multiple-cavity container, wherein a first cavity is used to store the veterinarily effective amount of one or more formamidine compounds, formamide compounds, or mixtures thereof, in a first veterinarily acceptable carrier and administer the composition to the animal therefrom; and wherein a second cavity is used to store the veterinarily effective amount of a 1-arylpyrazole compound in a second veterinarily acceptable carrier and administer the composition to the animal therefrom.
  • the multiple cavity container may have two or more cavities, that may contain different active agents and different carriers.
  • the multiple cavity containers may be used to include multiple doses of the same active agent for easy administration.
  • the multiple cavity container is a dual-cavity container.
  • Other embodiments include multiple cavity containers with three, four, or more cavities.
  • the multiple cavity containers will comprise delivery ports for administering the compositions.
  • the multiple cavity container is a dual cavity container that comprises: a first cavity defined by a front wall and a divider wall; and a second cavity defined by a rear wall the divider wall; wherein the first cavity is used to store and administer a veterinarily effective amount of at least one formamidine compounds, at least one formamide compounds, or mixtures thereof; and wherein the second cavity is used to store and administer a veterinarily effective amount of at least one 1-arylpyrazole compound.
  • an effective amount of the active compounds of the invention are administered via a dual-cavity container comprising: a first cavity defined by a front wall and a divider wall; a second cavity defined by a rear wall and a divider wall; wherein a veterinarily effective amount of at least one 1-arylpyrazole compound is administered via the first cavity; and wherein a veterinarily effective amount of at least one formamidine compound is administered via the second cavity.
  • a method wherein an effective amount of fipronil is administered via a first cavity of a multiple-cavity container and an effective amount of a formamidine compound is administered via a second cavity of a multiple-cavity container.
  • a method is provided wherein an effective amount of a 1-arylpyrazole compound of formula (I), (IA) or (IB) is administered via a first cavity of a dual-cavity container, and an effective amount of a formamidine of formula (II) is administered via a second cavity of a dual cavity container.
  • a method wherein an effective amount of fipronil is administered to the animal via a first cavity of a dual-cavity container, and an effective amount of amitraz is administered via a second cavity of a dual-cavity container.
  • a method wherein an effective amount of a 1-arylpyrazole compound of formula (IA) is administered to the animal via a first cavity of a dual-cavity container, and an effective amount of amitraz is administered via a second cavity of a dual-cavity container.
  • dual chamber dispensers which can be incorporated into the invention include but are not limited to the dispensers referred to in U.S. Patent 5,318,203; 5,353,961; 6,161729; 6,230,935, 6,883,295 and US Design Patent 404,972, the disclosures of which are hereby incorporated by reference in their entirety.
  • a composition of the invention may be delivered from a container having two or more cavities. Each cavity may include a component of the composition.
  • a container may include two distinct cavities, three distinct cavities or more.
  • Each cavity may include one or more components of the composition, which may be in the same or different carriers.
  • This aspect of the invention allows for the administration of combination of active compounds that may not be compatible together in the same carrier, or for the administration of compounds that require different carriers and/or excipients to provide sufficient stability and/or efficacy.
  • formulations comprising both a 1- arylpyrazole compound and a formamidine compound present together in certain carriers may not have sufficient storage shelf lives.
  • compositions and methods of the invention that provide for the administration of a 1-arylpyrazole compound and a formamidine compound via a dual cavity container are particularly useful because they allow the administration of highly efficacious compositions for treating parasitic infestations and also provide for an extended storage shelf life.
  • the dual-cavity container may include container 10 having thermoformed dual cavities, upper cavity 12 and lower cavity 14.
  • Container 10 may include front wall 16, rear wall 18, and divider wall 20 which may define the cavities of the container.
  • the front wall, rear wall and divider wall define a dual-cavity container.
  • divider wall 20 may be thinner than either front wall 16 or rear wall 18.
  • divider wall 20 may have a thickness in a range from about 5% to about 80% of either of the rear wall or front wall.
  • Some embodiments may include a divider wall having a thickness in a range from about 20% to about 70% of either the rear wall or the front wall.
  • the divider wall will have a thickness of from about 30% to about 70% or from about 40% to about 60% of either the front or rear wall.
  • the divider wall has a thickness of about 10% to about 40% of either of the rear wall or front wall.
  • some embodiments may include a divider wall having a thickness greater than a front wall, a rear wall and/or both the front and rear walls.
  • the front wall and the rear wall may be constructed from materials including, but not limited to films, rigid monolayers, laminate rigid films and/or any materials known in the art.
  • suitable materials include, but are not limited to, polyethylene terephthalate (PET), amorphous polyethylene terephthalate (APET), polyethylene terephthalate glycol (PETG) or crystalline polyethylene terephthalate (CPET), polyvinyl chloride (PVC), polypropylene (PP) polyethylene (PE), polyamide (PA), cycloolefin copolymers such as those known under the tradename COC ®, poly acrylonitrile (PAN) such as known under the tradename BAREX ® , and fluoropolymer or poly chlorotrifluoroethylene (PCTFE such as that as known under the tradename ACLAR ® .
  • PET polyethylene terephthalate
  • APET amorphous polyethylene terephthalate
  • PETG polyethylene terephthalate glycol
  • the divider wall may be constructed from materials including, but not limited to barrier films, flexible monolayers, laminate flexible films and /or any materials known in the art.
  • it includes polyester (PET), polypropylene (PP) polyethylene (PE), ethyl vinyl alcohol (EVOH), ethyl vinyl acetate (EVA), polyamide (PA), poly acrylonitrile (PAN) such as known under the tradename BAREX ® , fluropolymer or poly chlorotrifluoroethylene (PCTFE such as that as known under the tradename ACLAR ® and aluminium foil.
  • the aluminium foil has a thickness of less than 60 ⁇ m.
  • the multiple containers of the invention include, but are not limited to, PP/PE and PP/PE-EVOH-PE and PP/PP and PP/BAREX® and COCWPE and C(XX ) ZPH-I -VOl I-PIi and ('0( 1 W-ZPP and ( 1 OCZBARi-X(R' and A( I AR(RVAPi- IYl 5 L and ACL ⁇ RGO/ ⁇ PET/PE-EVOH-PE and ⁇ CLAR ⁇ /APET/PP and ACL ⁇ R®/ ⁇ PET/BAREX® and ACL ⁇ R' ⁇ /PI ⁇ T( i/Pi I and ⁇ CI AROO/I 8 Fl ( i/PI • -!
  • LPDE Based Or Polyefins Blend Monolayer BAREX® Monolayer, LDPE/ Aluminum Foil /LDPE, BAREX ⁇ /Aluminum Foil/BAREX® LDPE/EVOH/LDPE, Sealable PET/PE/Sealable PET, Sealable PET/Foil/ Sealable PET, and PE/Nylon/PE.
  • Additional combinations of materials suitable for the divider wall of the container of the present invention include, but are not limited to, PE-EVOH-PEAlu foil/PE-EVOH-PE and PE- EVOH-EVA-PE/Alu foil/PE-EVA-EVOH-PE and PP/Alu foil /PP and PP/PE/Alu foil/PE/PP and PE/ ACLAR®/PE and PP/ ACLAR ⁇ /PP and BAREX®/ ACLAR®/BAREX® and PE- EVOH-PE/PA/PE-EVOH-PE.
  • the walls may be coupled along a part of their perimeter to define the cavities.
  • the walls may be bonded together along the perimeter.
  • Figure 1 depicts upper cavity 12 and lower cavity 14 having substantially the same proximal ends 22 and distal ends 24. Alternately, some embodiments may include ends which vary.
  • Figure 2 shows upper cavity 12 being shorter at distal end 24 than distal end 24' of lower cavity 14.
  • cavities 12, 14 may have different volumes. For example,
  • Figure 2 depicts upper cavity 12 having a smaller volume than lower cavity 14.
  • a multi-cavity container may be used to deliver a liquid, a paste, a cream, powder, and/or granules.
  • Multi-cavity containers may be to deliver drugs, cosmetics, food, household supplies, shampoos, conditioners, detergent, and/or adhesives.
  • two or more components may be delivered by squeezing or pressing the external wall of the multi-cavity container.
  • the components in the cavities may differ.
  • upper cavity 12 may include a component which differs from lower cavity 14.
  • upper cavity 12 and lower cavity 14 may include substantially similar components.
  • container 10 may include indenture 26. Indenture 26 may be positioned to allow for uniform delivery of the components.
  • indenture 26 may positioned on front wall 16 defining upper cavity 12. In some embodiments, there may be an indent positioned on both the front and rear walls. Indentures may be shaped to conform to a finger. Indentures may also be shaped to conform to a thumb. In some embodiments, indentures may allow for improved gripping.
  • Container 10 may include transparent external walls.
  • the front and rear walls may be configured to allow for accurate and full squeezing.
  • a multi-cavity container may be configured to dispense without any tilt, bend, and/or movement after opening.
  • Opening mechanism 28 may include but is not limited to a fracture line 32, a die cut, a perforation or any other design known in the art.
  • opening mechanism may be a die cut.
  • Opening mechanism 28 may include one half moon shape 31.
  • a half moon shaped die cut may be made.
  • two half moon shaped die cuts 31 and 31' may be made perpendicular to a fracture line 32.
  • an opening mechanism may have any geometry including but not limited to a line, a curve, or any geometry known in the art.
  • the opening mechanism may tear a divider wall with no elongation. Further, the opening mechanism may be configure so that there are no sharp edges to the standard perpendicular connection between fracture line and perimeter of rigid front/ rear walls.
  • Figure 6 depicts opening mechanism 28 as a line. As shown in Figures 6-8, some embodiments may include tip 30 which may be twisted off along opening mechanism 28.
  • a multi-cavity container may be configured to dispense without any tilt, bend, and/or movement after opening.
  • Some embodiments may include marks to position front and rear walls prior to coupling.
  • materials for the construction of the walls may be preprinted with a printing mark to customize each side with perfect positioning.
  • a strip of containers may be connected prior to use.
  • a container may be constructed from a central ribbon for the divider wall and an external ribbon for the front and rear walls.
  • a thermoforming station may form the front and rear walls prior to a feeding station delivering the central ribbon. Then, the wall perimeters may be coupled together, for example, by bonding or welding.
  • the thermoforming process is a very well known process, and has been described in U.S. Patent Nos. 5,223,073, 6,883,295, and in International Application Publication Nos. WO 2004/069658 A2, WO 2005/094330 and WO 2008/065512, all incorporated herein by reference in their entirety.
  • some embodiments may include a cooling period in the thermoforming station prior to coupling the wall perimeters.
  • Some embodiments may include positioning the central ribbon to extend beyond the external ribbon. Positioning the ribbons in this manner may ensure a complete seal between the cavities.
  • a tenth aspect of the invention is a kit for the treatment or prevention of a parasitic infestation in an animal, comprising one or more 1-arylpyrazole compound(s) in a first veterinarily acceptable carrier, one or more formamidine compound(s) in a second veterinarily acceptable carrier, and a multiple cavity container; wherein the one or more 1- arylpyrazole compound(s) in a first veterinarily acceptable carrier is in a first cavity of the multiple cavity container and the one or more formamidine compound(s) in a second veterinarily acceptable carrier is in a second cavity of the multiple cavity container; and wherein the first cavity is defined by a front wall and a divider wall; and the second cavity defined by a rear wall the divider wall.
  • compositions comprising formamidine compounds in combination with some 1-arylpyrazole compounds in certain solvent carriers do not have sufficient storage shelf lives for commercial use.
  • inventive kit described herein allow for the long term storage and subsequent administration of compositions comprising 1-arylpyrazoles and formamidines.
  • certain synergistic compositions of 1-arylpyrazoles and amitraz may be stored and administered using the kit without degradation for long periods of time, allowing for the superior control of parasites in animals.
  • the kit may include any of the 1-arylpyrazle compositions described above in one or more of the cavities, including any of the veterinarily acceptable carriers previously described.
  • the first veterinarily acceptable carrier that is combined with the 1-arylpyrazole compound(s) includes, but is not limited to, C 1 -C 1O alcohols or esters thereof (including acetates, such as ethyl acetate, butyl acetate and the like), C 1O -C 18 saturated fatty acids or esters thereof, C 1O -C 18 monounsaturated fatty acids or esters thereof, monoesters or diesters of aliphatic diacids, glycerol monoesters (e.g. monoglycerides), glycerol diesters (e.g. diglycerides), glycerol triesters (e.g.
  • triglycerides such as triacetin
  • glycols such as triacetin
  • glycol ethers such as glycol esters or glycol carbonates
  • PEGs polyethylene glycols of various grades
  • monoethers such as diethers, monoesters or diesters thereof (e.g. diethylene glycol monoethyl ether), or mixtures thereof.
  • the first veterinarily acceptable carrier includes, but is not limited to, acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate (also known as CERAPHYL 230), butyl diglycol, dipropylene glycol n- butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone including N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, amides including dimethylformamide and dimethylacetamide, or any combination thereof.
  • the second veterinarily acceptable carrier includes, but is not limited to, aryl ethers including alkoxybenzene compounds; carboxylic acid esters, including aliphatic and aromatic carboxylic acids such as benzoic acid esters, and compounds with multiple carboxylate groups; aliphatic ketones, saturated aliphatic ketones, cyclic ketones, or mixtures thereof.
  • the second veterinarily acceptable carrier includes, but is not limited to, C 1 -C 1O carboxylic acid esters, phenyl carboxylic acid esters, carboxylic acid benzyl esters, benzoic acid C 1 -C 4 alkyl esters, Ci-C 6 saturated aliphatic ketones, and mixtures thereof.
  • the second veterinarily acceptable carrier includes, but is not limited to, methoxybenzene, butyl acetate, benzyl acetate, methyl isobutyl ketone, ethyl benzoate, benzyl benzoate, octyl acetate or mixtures thereof.
  • the second veterinarily acceptable carrier includes one or more solvent(s) with a dielectric constant of about 2 to about 30.
  • the second veterinarily acceptable carrier comprises a solvent with a dielectric constant of about 2 to about 40, 2 to about 20, 5 to about 30, or 10 to about 30.
  • the second veterinarily acceptable carrier comprises one or more solvents with a dielectric constant of about 2 to about 15 or about 3 to about 10. In still another embodiment, the dielectric constant of the one or more solvents is about 3.5 to about
  • the dielectric constant of the one or more solvents is about 4 to about 6.5.
  • the second veterinarily acceptable carrier includes one or more aprotic solvents, preferably polar aprotic solvents, with dielectric constants of about 2 to about 30.
  • the second veterinarily acceptable carrier comprises one or more aprotic solvent(s) with a dielectric constant of about 2 to about 40, 2 to about 20, 5 to about 30, or 10 to about 30.
  • the second veterinarily acceptable carrier comprises one or more aprotic solvent(s) with a dielectric constant of about 2 to about 15 or about 3 to about 10. In still another embodiment, the dielectric constant of the one or more aprotic solvent(s) is about 3.5 to about 10. In another embodiment, the dielectric constant of the one or more aprotic solvent(s) is about 4 to about 6.5. In some preferred embodiments, the solvents will be polar aprotic solvents with dielectric constants in the ranges described above. In another embodiment, the solvent(s) with a dielectric constants of about 2 to about
  • the second veterinarily acceptable carrier will contain less than about 0.5% or less than about 0.3% (w/w) water.
  • the solvent with a dielectric constant of about 2 to about 30 will typically contain less than 0.2% (w/w) water.
  • the solvent will contain less than about 0.1%, or less than about 0.05% or less than about 0.025% (w/w) water.
  • the solvent will contain from about 0.0001% (w/w) to about 0.5% (w/w) water. More typically, the solvent with a dielectric constant of about 2 to about 30 will contain about 0.0001% to about 0.3%, about 0.001% to about 0.3%, about 0.001% to about 0.1% or about 0.001% to about 0.05% (w/w) water.
  • the solvent will contain from about 0.001% to about 0.025% (w/w) water.
  • the compositions of the invention can be in a variety of forms suitable for different forms of administration including, but are not limited to, oral formulations, injectable formulations, and topical, dermal or subdermal formulations.
  • compositions of the invention may be in a form suitable for oral use, for example, as baits (see, e.g., U.S. Patent No. 4,564,631, incorporated herein by reference), dietary supplements, troches, lozenges, chewables, tablets, hard or soft capsules, emulsions, aqueous or oily suspensions, aqueous or oily solutions, oral drench formulations, dispersible powders or granules, syrups or elixirs, enteric formulations or pastes.
  • compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, bittering agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets may contain the active ingredient in admixture with non-toxic, pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc, the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate
  • granulating and disintegrating agents for example, corn starch, or alginic acid
  • binding agents for example starch,
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in U.S. Patent Nos. 4,256,108; 4,166,452; and 4,265,874, which are incorporated herein by reference in their entirety, to form osmotic therapeutic tablets for controlled release.
  • Formulations for oral use may be hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin.
  • Capsules may also be soft gelatin capsules, wherein the active ingredient is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • compositions of the invention may also be in the form of oil-in- water or water-in- oil emulsions.
  • the oily phase maybe a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening agents, bittering agents, flavoring agents, and/or preservatives.
  • the composition of the invention is in the form of a microemulsion.
  • Microemulsions are well suited as the liquid carrier vehicle. Microemulsions are quaternary systems comprising an aqueous phase, an oily phase, a surfactant and a cosurfactant. They are translucent and isotropic liquids. Microemulsions are composed of stable dispersions of microdroplets of the aqueous phase in the oily phase or conversely of microdroplets of the oily phase in the aqueous phase. The size of these microdroplets is less than 200 nm (1000 to 100,000 nm for emulsions).
  • the interfacial film is composed of an alternation of surface- active (SA) and co-surface-active (Co-SA) molecules which, by lowering the interfacial tension, allows the microemulsion to be formed spontaneously.
  • SA surface- active
  • Co-SA co-surface-active
  • the oily phase can be formed from mineral or vegetable oils, from unsaturated polyglycosylated glycerides or from triglycerides, or alternatively from mixtures of such compounds.
  • the oily phase comprises of triglycerides.
  • the triglycerides are medium-chain triglycerides, for example Cg-Cio caprylic/capric triglyceride.
  • Another embodiment of the oily phase will represent a % v/v range selected from the group consisting of about 2 to about 15%; about 7 to about 10%; and about 8 to about 9% v/v of the microemulsion.
  • the aqueous phase includes, for example water or glycol derivatives, such as propylene glycol, glycol ethers, polyethylene glycols or glycerol.
  • glycol derivatives such as propylene glycol, glycol ethers, polyethylene glycols or glycerol.
  • the glycol is selected from the group consisting of propylene glycol, diethylene glycol monoethyl ether, dipropylene glycol monoethyl ether and mixtures thereof.
  • the aqueous phase will represent a proportion from about 1 to about 4% v/v in the microemulsion.
  • Surfactants for the microemulsion include diethylene glycol monoethyl ether, dipropyelene glycol monomethyl ether, polyglycolyzed Cg-Cio glycerides or polyglyceryl-6 dioleate.
  • the cosurfactants include short-chain alcohols, such as ethanol and propanol.
  • the cosurfactant to surfactant ratio will be from about 1/7 to about 1/2. In another embodiment for the amount of cosurfactant, the ratio will be from about 25 to about 75% v/v of surfactant and from about 10 to about 55% v/v of cosurfactant in the microemulsion.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, atachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as sucrose, saccharin or aspartame, bittering agents, and flavoring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid or other known preservatives.
  • Aqueous suspensions may contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxy- propylmethylcellulose, sodium alginate, polvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide, with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorb
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents and/or bittering agents, such as those set forth above.
  • preservatives for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents and/or bittering agents, such as those set forth above.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
  • Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring agent(s) and/or coloring agent(s).
  • sweetening agents for example, glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative, flavoring agent(s) and/or coloring agent(s).
  • the composition can be in paste form.
  • paste form examples include but are not limited to those described in U.S. Patent Nos. 6,787,342 and 7,001,889, both of which are incorporated herein by reference.
  • the paste can also contain fumed silica; a viscosity modifier; a carrier; optionally, an absorbent; and optionally, a colorant, stabilizer, surfactant, or preservative.
  • the process for preparing a paste formulation comprises the steps of:
  • step (c) allowing the intermediate formed in (b) to settle for a time sufficient in order to allow the air entrapped during step (b) to escape;
  • step (a) can be the last step.
  • the formulation is a paste containing the active agent compound, fumed silica, a viscosity modifier, an absorbent, a colorant; and a hydrophilic carrier which is a triacetin, a monoglyceride, a diglyceride, or a triglyceride.
  • the paste may also include a viscosity modifier including, but is not limited to, PEG 200, PEG 300, PEG 400, PEG 600, monoethanolamine, triethanolamine, glycerol, propylene glycol, polyoxyethylene (20) sorbitan mono-oleate (polysorbate 80 or Tween 80), or polyoxamers (e.g., Pluronic L 81); an absorbent including, but not limited to, magnesium carbonate, calcium carbonate, starch, or cellulose and its derivatives.
  • a viscosity modifier including, but is not limited to, PEG 200, PEG 300, PEG 400, PEG 600, monoethanolamine, triethanolamine, glycerol, propylene glycol, polyoxyethylene (20) sorbitan mono-oleate (polysorbate 80 or Tween 80), or polyoxamers (e.g., Pluronic L 81); an absorbent including, but not limited to, magnesium carbonate, calcium carbonate, starch, or cellulose and its
  • Colorants may be added to the inventive formulations.
  • Colorants contemplated by the present invention are those commonly known in the art. Specific colorants include, for example, dyes, FD&C Blue #1 Aluminum Lake, caramel, colorant based upon iron oxide or a mixture of any of the foregoing. Especially preferred are organic dyes and titanium dioxide. Preferred ranges include from about 0.5% to about 25%.
  • compositions may be in the form of a sterile injectable solutions or aqueous or oleagenous suspensions. These suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-aceptable diluent or solvent, for example, as a solution in 1,3-butane diol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used.
  • Preservatives, such as phenol or benzyl alcohol, may be used.
  • Topical, dermal and subdermal formulations can include emulsions, creams, ointments, gels, pastes, powders, shampoos, pour-on formulations, ready-to-use formulations, spot-on solutions and suspensions.
  • Topical application of an inventive compound or of a composition including at least one inventive compound among active agent(s) therein, a spot- on composition can allow for the inventive compound to be distributed through the glands (e.g.
  • sebaceous glands of the animal and/or allow active agent(s) to achieve a systemic effect (plasma concentration) or throughout the haircoat.
  • the glands can act as a reservoir, whereby there can be a long-lasting, e.g. 1-2 months effect or longer.
  • Cotchet and co-workers reported the distribution of fipronil, a 1- arylpyrazole compound, to the stratum corneum, the viable epidermis and the sebaceous glands and epithelial layers of beagle dogs after spot-on administration (see Cochet et al., Eur. J. Drug Metab. Pharmacokinet.., 1997, 22(3), 211-216).
  • fipronil is displaced from the point of application and distributed to the whole skin, where it was persistently detected for up to 56 days after treatment.
  • Spot-on formulations are typically applied in a localized region which refers to an area other than the entire animal. In one embodiment of a localized region, the location is between the shoulders. In another embodiment, the localized region is a stripe, e.g. a stripe from head to tail of the animal.
  • pour-on formulations are described, for example, in U.S. Patent No. 6,010,710, which is incorporated herein by reference.
  • the pour-on formulations are advantageously oily, and generally comprise a diluent or vehicle and also a solvent (e.g. an organic solvent) for the active ingredient if the latter is not soluble in the diluent.
  • Pour-on formulation may be administered to livestock animals such as cattle and sheep.
  • the process comprises applying the solution to livestock animals before they arrive in the Feed Lot, it being possible for this application to be the final one before the animals are slaughtered.
  • compositions of the invention can also be formed in a collar such as those described in U.S. Patent 5,885,607, which is incorporated herein by reference.
  • matrices usually used to make collars may be used.
  • the collars which may be mentioned are matrices based on PVC (polyvinyl chloride), as described in U.S. Patent Nos. 3,318,769; 3,852,416; 4,150,109 and 5,437,869,
  • the plasticizers may be chosen in particular from adipates, phthalates, phosphates and citrates. In another embodiment of the collar, one or more plasticizers are also added to the
  • plasticizers being chosen in particular from the following compounds: diethyl phthalate, dioctyl sebacate, dioctyl adipate, diisodecyl phthalate, acetyl tributyl citrate, diethyl hexyl phthalate, di-n-butyl phthalate, benzyl butyl phthalate, acetyl tributyl citrate, tricresyl phosphate, and 2-ethylhexyl diphenyl phosphate.
  • a PVC matrix will be used in the presence of a primary remanent plasticizer and a secondary plasticizer, in particular according to EP 0 539 295 and EP 0 537 998.
  • secondary plasticizers mention may be made of the following products: acetyl triethyl citrate, triethyl citrate, triacetin, diethylene glycol monoethyl ether, triphenyl phosphate.
  • a common stabilizer may also be added thereto.
  • the term external device should be understood to refer to any device which can be attached externally to the animal in order to provide the same function as a collar.
  • the active agent is present in the formulation at a concentration of about 0.05 to about 40% (w/v). In another embodiment of the invention, the active agent is present in the formulation as a concentration from about 1 to about 30% or about 1 to about 20% (w/v). In yet another embodiment of the invention, the active agent is present in the formulation as a concentration from about 5 to about 15% (w/v). In still another embodiment of the invention, the active agent is present in the formulation as a concentration about 10% (w/v), about 20% (w/v) or about 30% (w/v).
  • the combination of 1-arylpyrazole and formamidine is present in the formulation at a concentration of about 2% to about 55% (w/v); about 10% to about 35% w/v; or about 18% to about 27% w/v.
  • the amount of 1-arylpyrazole is present in the formulation as a concentration of about 1% to about 25% (w/v); about 5% to about 15% (w/v); or about 8% to about 12% (w/v).
  • the amount of formamidine in the formulations is about 1% to about 30 (w/v); about 5% to about 20% (w/v); or about 10% to about 15% (w/v).
  • the veterinarily acceptable carrier will generally comprise a diluent or vehicle and also a solvent (e.g. an organic solvent) for the active ingredient if the latter is not soluble, not stable or is degraded in the diluent.
  • a solvent e.g. an organic solvent
  • Organic solvents that can be used in the invention include those described above, and include but are not limited to: acetyltributyl citrate, oleic acid, fatty acid esters such as the dimethyl ester, diisobutyl adipate, diisopropyl adipate (also known as CERAPHYL 230), ketones including acetone, methylisobutyl ketone (MIK) and methyl ethyl ketone and the like, acetonitrile, benzyl alcohol, methanol, ethyl alcohol, isopropanol, butanol, aromatic ethers such as anisole, butyl diglycol, amides including dimethylacetamide and dimethylformamide, dimethyl sulfoxide, propylene glycol monomethyl ether, propylene glycol monoethyl ether, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl
  • the pharmaceutically or veterinarily acceptable carrier of the formulation comprises C 1 -C 1O alcohols or esters thereof (including acetates, such as ethyl acetate and the like), C 1O -C 18 saturated fatty acids or esters thereof, C 1O -C 18 monounsaturated fatty acids or esters thereof, monoesters or diesters of aliphatic diacids, glycerol monoesters (e.g. monoglycerides), glycerol diesters (e.g. diglycerides), glycerol triesters (e.g.
  • triglycerides such as triacetin
  • glycols such as triacetin
  • glycol ethers such as glycol esters or glycol carbonates
  • PEGs polyethylene glycols of various grades
  • monoethers such as diethers, monoesters or diesters thereof (e.g. diethylene glycol monoethyl ether), or mixtures thereof.
  • the organic solvents may comprise diisopropyl adipate, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, 2-pyrrolidone including N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, oleic acid, or a mixture of at least two of these solvents.
  • preferred solvents include C 1 -C 1O esters of carboxylic acids such as butyl or octyl acetate.
  • Particularly preferred solvents include diethyleneglycol monoethyl ether, triacetin, butyl acetate and octyl acetate, and mixtures thereof.
  • the organic solvent will have a dielectric constant of between about 2 to about 35, between about 10 to about 35, or between about 20 to about 30. In other embodiments, the solvent will have a dielectric constant of between about 2 and about 20, or between about 2 and about 10.
  • the content of this organic solvent in the overall composition will represent the complement to 100% of the composition.
  • the organic solvents with dielectric constants within these ranges will typically be aprotic solvents, preferably polar aprotic solvents.
  • the carrier may comprise a mixture of solvents.
  • the formulations comprise an organic solvent and an organic co-solvent.
  • the formulations comprise a co-solvent having a boiling point of below about 300 ° C or below about 250 ° C.
  • the co-solvent has a boiling point of below about 200° C, or below about 130° C.
  • the co-solvent has a dielectric constant of between about 2 to about 40 or between about 10 to about 40.
  • the co- solvent has a dielectric constant of between about 20 to about 30.
  • the co-solvent has a dielectric constant of between about 2 to about 10.
  • the co-solvent may be present in the composition in a organic co- solvent/organic solvent weight/weight (WAV) ratio of between about 1/15 to about 1/2.
  • WAV organic co- solvent/organic solvent weight/weight
  • the co-solvent is volatile so as to act as a drying promoter, and is miscible with the organic solvent and may or may not be miscible with water.
  • the solvent will be used in proportion with the concentration of the active agent compound and its solubility in this solvent. It will be sought to have the lowest possible volume. The vehicle makes up the difference to 100%.
  • a vehicle or diluent can be dimethyl sulfoxide (DMSO), glycol derivatives such as, for example, propylene glycol, glycol ethers, polyethylene glycols or glycerol.
  • DMSO dimethyl sulfoxide
  • glycol derivatives such as, for example, propylene glycol, glycol ethers, polyethylene glycols or glycerol.
  • plant oils such as, but not limited to soybean oil, groundnut oil, castor oil, corn oil, cotton oil, olive oil, grape seed oil, sunflower oil, etc.
  • mineral oils such as, but not limited to, petrolatum, paraffin, silicone, etc.
  • an emollient and/or spreading and/or film- forming agent will be added.
  • the emollient and/or spreading and/or film- forming agents are those agents selected from
  • polyvinylpyrrolidone polyvinyl alcohols, copolymers of vinyl acetate and vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol, polyoxyethylenated sorbitan esters; lecithin, sodium carboxymethylcellulose, silicone oils, polydiorganosiloxane oils (such as polydimethylsiloxane (PDMS) oils), for example those containing silanol functionalities, or a 45V2 oil,
  • PDMS polydimethylsiloxane
  • anionic surfactants such as alkaline stearates, sodium, potassium or ammonium stearates; calcium stearate, triethanolamine stearate; sodium abietate; alkyl sulfates (e.g. sodium lauryl sulfate and sodium cetyl sulfate); sodium dodecylbenzenesulphonate, sodium dioctylsulphosuccinate; fatty acids (e.g. those derived from coconut oil),
  • cationic surfactants such as water-soluble quaternary ammonium salts of formula N + R 1 R 11 R" 'R" "Y " , in which the R radicals are optionally hydroxylated hydrocarbon radicals and Y " is an anion of a strong acid such as the halide, sulfate and sulphonate anions; cetyltrimethylammonium bromide is among the cationic surfactants which can be used,
  • polysorbate 80 polyoxyethylenated alkyl ethers; polyoxypropylated fatty alcohols such as polyoxypropylene-styrol ether; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids, copolymers of ethylene oxide and propylene oxide,
  • amphoteric surfactants such as the substituted lauryl compounds of betaine, and
  • the emollient is used in a proportion selected from the group consisting of from about 0.1 to about 10%, and about 0.25 to about 5%, by volume.
  • the composition in ready-to-use solution form as is described, for example, in U.S. Patent No. 6,395,765, which is incorporated herein by reference.
  • the ready-to-use solution can contain a crystallization inhibitor, an organic solvent and an organic co-solvent.
  • the crystallization inhibitor can be present in a proportion of about 1 to about 30% (w/v). Typically, the crystallization inhibitor may be present in a proportion of about 1% to about 20% (w/v) or about 5% to about 15% (w/v). Acceptable inhibitors are those whose addition to the formulation inhibits the formation of crystals when the formulation is applied. In some embodiments, formulations may include compounds that function as crystallization inhibitors other than those listed herein.
  • the suitability of a crystallization inhibitor may be determined by testing if it will sufficiently inhibit the formation of crystals so that a sample containing 10% (w/v) of the 1-arylpyrazole in a solvent as described above with 10% (w/v) of the crystallization inhibitor will result in less 20, preferably less than 10 crystals when placed on a glass slide at 20 ° C for 24 hours.
  • Crystallization inhibitors which are useful for the invention include but are not limited to:
  • polyvinylpyrrolidone polyvinyl alcohols, copolymers of vinyl acetate and of vinylpyrrolidone, 2-pyrrolidone including N-methylpyrrolidone, dimethylsufoxide, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol or polyoxyethylenated esters of sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic derivatives, such as methacrylates and polymers derived from acrylic monomers, a solvent as described herein that inhibits the crystallization of the active agent, and others; (b) anionic surfactants, such as alkaline stearates (e.g.
  • sodium, potassium or ammonium stearate calcium stearate or triethanolamine stearate; sodium abietate; alkyl sulfates, which include but are not limited to sodium lauryl sulfate and sodium cetyl sulfate; sodium dodecylbenzenesulphonate or sodium dioctyl sulphosuccinate; or fatty acids (e.g. coconut oil);
  • cationic surfactants such as water-soluble quaternary ammonium salts of formula N + R'R"R'"R""Y " , in which the R radicals are identical or different optionally hydroxylated hydrocarbon radicals and Y " is an anion of a strong acid, such as halide, sulfate and sulphonate anions; cetyltrimethylammonium bromide is one of the cationic surfactants which can be used;
  • non-ionic surfactants such as optionally polyoxyethylenated esters of sorbitan, e.g. Polysorbate 80, or polyoxyethylenated alkyl ethers; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids or copolymers of ethylene oxide and of propylene oxide;
  • non-ionic surfactants such as optionally polyoxyethylenated esters of sorbitan, e.g. Polysorbate 80, or polyoxyethylenated alkyl ethers
  • polyethylene glycol stearate polyoxyethylenated derivatives of castor oil, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids or copolymers of ethylene oxide and of propylene oxide
  • amphoteric surfactants such as substituted lauryl compounds of betaine; or (g) a mixture of at least two of the compounds listed in (a)-(f) above.
  • a crystallization inhibitor pair will be used.
  • Such pairs include, for example, the combination of a film-forming agent of polymeric type and of a surface- active agent. These agents can be selected from the compounds mentioned above as crystallization inhibitor.
  • the agents are of the polymeric type which include but are not limited to the various grades of polyvinylpyrrolidone, polyvinyl alcohols, and copolymers of vinyl acetate and of vinylpyrrolidone.
  • the agents include but are not limited to those made of non-ionic surfactants.
  • the agent is a polyoxyethylenated esters of sorbitan.
  • the agents include the various grades of polysorbate, for example
  • the film-forming agent and the surface- active agent can be incorporated in similar or identical amounts within the limit of the total amounts of crystallization inhibitor mentioned above.
  • the pair thus constituted secures, in a noteworthy way, the objectives of absence of crystallization on the coat and of maintenance of the cosmetic appearance of the skin or fur, that is to say without a tendency towards sticking or towards a sticky appearance, despite the high concentration of active material.
  • the formulation can also comprise an antioxidizing agent intended to inhibit oxidation in air, this agent being present in a proportion selected from a range consisting of about 0.005 to about 1% (w/v), and about 0.01 to about 0.05% (w/v).
  • the agents are those conventional in the art and include, but are not limited to, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, sodium metabisulphite, propyl gallate, sodium thiosulfate or a mixture of not more than two of them.
  • composition adjuvants are well known to the practitioner in this art and may be obtained commercially or through known techniques. These concentrated compositions are generally prepared by simple mixing of the constituents as defined above. Advantageously, the starting point is to mix the active material in the main solvent and then the other ingredients or adjuvants are added.
  • the volume applied is not restricted as long as the amount of substance administered is shown to be safe and efficacious. Typically, the volume applied depends on the size and weight of the animal as well as the concentration of active, the extent of infestation by parasites and the type of administration.
  • the volume applied is typically of the order of about 0.3 to about 1 ml, or about 0.3 ml to about 5 ml, or about 0.3 ml to about 10 ml. In other embodiments, the volume may be about 4 ml to about 7 ml. For larger animals, the volume may be higher including, but not limited to, up to 10 ml, up to 20 ml or up to 30 ml, or higher. In one embodiment of the volume, the volume is on the order of about 0.5 ml to about 1 ml for cats, and on the order of about 0.3 to about 3 ml or 4 ml for dogs, depending on the weight of the animal.
  • application of a spot-on formulation according to the present invention can also provide long-lasting and broad-spectrum efficacy when the solution is applied to the mammal or bird.
  • the spot-on formulations provide for topical administration of a concentrated solution, suspension, microemulsion or emulsion for intermittent application to a spot on the animal, generally between the two shoulders (solution of spot-on type).
  • Spot-on formulations are well known techniques for topically delivering an antiparasitic agent to a limited area of the host.
  • U.S. Patent Nos. 5,045,536 6,426,333; 6,482,425; 6,962,713; and 6,998,131 all incorporated herein by reference, describe spot-on formulations.
  • WO 01/957715 also incorporated herein by reference, describes a method for controlling ectoparasites in small rodents as well as interrupting or preventing the diseases caused by arthropods or small rodents, which comprise applying topical formulations, such as spot-on compositions, to the skin, or hair of the rodents.
  • the carrier can be a liquid carrier vehicle as described, for example, in U.S. Patent No. 6,426,333.
  • Liquid carriers for spot-on formulations include the organic solvents and co-solvents described above, among other solvents known in the art.
  • the liquid carrier vehicle can optionally contain a crystallization inhibitor such as the crystallization inhibitors described above, or mixtures thereof.
  • Spot-on formulations may be prepared by dissolving the active ingredients into the pharmaceutically or veterinary acceptable vehicle.
  • the spot-on formulation can be prepared by encapsulation of the active ingredient to leave a residue of the therapeutic agent on the surface of the animal.
  • These formulations will vary with regard to the weight of the therapeutic agent in the combination depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host.
  • Dosage forms may contain from about 0.5 mg to about 5 g of an active agent.
  • the dosage is from about 1 mg to about 500 mg of an active agent, typically about 25 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 800 mg, or about 1000 mg.
  • Additional veterinary/pharmaceutical active ingredients may be used with the compositions of the invention.
  • the additional active agents may include, but are not limited to, acaricides, anthelmintics, anti-parasitics and insecticides.
  • Anti-parasitic agents can include both ectoparasiticidal and endoparasiticidal agents.
  • Veterinary pharmaceutical agents that may be included in the compositions of the invention are well-known in the art (see e.g. Plumb' Veterinary Drug Handbook, 5 th Edition, ed. Donald C. Plumb, Blackwell Publishing, (2005) or The Merck Veterinary Manual, 9 th Edition, (January 2005)) and include but are not limited to acarbose, acepromazine maleate, acetaminophen, acetazolamide, acetazolamide sodium, acetic acid, acetohydroxamic acid, acetylcysteine, acitretin, acyclovir, albendazole, albuterol sulfate, alfentanil, allopurinol, alprazolam, altrenogest, amantadine, amikacin sulfate, aminocaproic acid, aminopentamide hydrogen sulfate, aminophylline/theophylline, amiodarone, amitriptyline,
  • arylpyrazole compounds such as phenylpyrazoles described above in the Background
  • arylpyrazole compounds include but are not limited to those described in U.S. Patent Nos. 6,001,384; 6,010,710; 6,083,519; 6,096,329; 6,174,540; 6,685,954 and 6,998,131 (all of which are incorporated herein by reference, each assigned to Merial, Ltd., Duluth, GA).
  • one or more macrocyclic lactones or lactams which act as an acaricide, anthelmintic agent and/or insecticide, can be added to the compositions of the invention.
  • the macrocyclic lactones include, but are not limited to, avermectins, such as abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, ML- 1,694, 554 and milbemycins, such as milbemectin, milbemycin D, moxidectin and nemadectin. Also included are the 5-oxo and 5-oxime derivatives of said avermectins and milbemycins.
  • Examples of combinations of arylpyrazole compounds with macrocyclic lactones include but are not limited to those described in U.S. Patent Nos. 6,426,333; 6,482,425; 6,962,713 and 6,998,131 (all incorporated herein by reference - each assigned to Merial, Ltd., Duluth, GA).
  • the macrocyclic lactone compounds are known in the art and can easily be obtained commercially or through synthesis techniques known in the art. Reference is made to the widely available technical and commercial literature.
  • avermectins ivermectin and abamectin
  • Macrocyclic lactones are either natural products or are semi-synthetic derivatives thereof.
  • the structure of the avermectins and milbemycins are closely related, e.g., by sharing a complex 16-membered macrocyclic lactone ring.
  • the natural product avermectins are disclosed in U.S. Patent No. 4,310,519 and the 22,23-dihydro avermectin compounds are disclosed in U.S. Patent No. 4,199,569. Mention is also made of U.S. Patent Nos. 4,468,390, 5,824,653, EP 0 007 812 Al, U.K. Patent Specification 1 390 336, EP 0 002 916, and New Zealand Patent No.
  • the class of acaricides or insecticides known as insect growth regulators can also be added to the compositions of the invention.
  • IGRs insect growth regulators
  • Compounds belonging to this group are well known to the practitioner and represent a wide range of different chemical classes. These compounds all act by interfering with the development or growth of the insect pests.
  • Insect growth regulators are described, for example, in U.S. Patent Nos. 3,748,356, 3,818,047, 4,225,598, 4,798,837, 4,751,225, EP 0 179 022 or U.K. 2 140 010 as well as U.S. Patent Nos. 6,096,329 and 6,685,954 (all incorporated herein by reference).
  • IGRs suitable for use include but are not limited to methoprene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, novaluron, pyrethroids, formamidines such as amitraz, l-(2, 6-difluorobenzoyl)-3-(2-fluoro- 4-(trifluoromethyl)phenylurea, and novaluron.
  • adulticide insecticides and acaricides can also be added to the composition of the invention.
  • these include pyrethrins (which include cinerin I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II and mixtures thereof) and pyrethroids, and carbamates (which include but are not limited to benomyl, carbanolate, carbaryl, carbofuran, meththiocarb, metolcarb, promacyl, propoxur, aldicarb, butocarboxim, oxamyl, thiocarboxime and thiofanox).
  • pyrethrins which include cinerin I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II and mixtures thereof
  • carbamates which include but are not limited to benomyl, carbanolate, carbaryl, carbofuran, me
  • the compositions of the invention may include one or more antinematodal agents including, but not limited to, active agents in the benzimidazoles, imidazothiazoles, tetrahydropyrimidines, organophosphates class of compounds.
  • benzimidazoles including, but not limited to, thiabendazole, cambendazole, parbendazole, oxibendazole, mebendazole, flubendazole, fenbendazole, oxfendazole, albendazole, cyclobendazole, febantel, thiophanate and its o,o-dimethyl analogue may be included in the compositions.
  • compositions may include an imidazothiazole compounds including, but not limited to, tetramisole, levamisole and butamisole.
  • compositions of the invention may include tetrahydropyrimidine active agents including, but not limited to, pyrantel, oxantel, and morantel.
  • Suitable organophosphate active agents include, but are not limited to, coumaphos, trichlorfon, haloxon, naftalofos and dichlorvos, heptenophos, mevinphos, monocrotophos, TEPP, and tetrachlorvinphos .
  • the compositions may include the antinematodal compounds phenothiazine, piperazine as the neutral compound and in various salt forms, diethylcarbamazine, phenols such as disophenol, arsenicals such as arsenamide, ethanolamines such as bephenium, thenium closylate, and methyridine; cyanine dyes including pyrvinium chloride, pyrvinium pamoate and dithiazanine iodide; isothiocyanates including bitoscanate, suramin sodium, phthalofyne, and various natural products including, but not limited to, hygromycin B, ⁇ -santonin and kainic acid.
  • compositions of the invention may include antitrematodal agents.
  • Suitable antitrematodal agents include, but are not limited to, the miracils such as miracil D and mirasan; praziquantel, clonazepam and its 3-methyl derivative, oltipraz, lucanthone, hycanthone, oxamniquine, amoscanate, niridazole, nitroxynil, various bisphenol compounds known in the art including hexachlorophene, bithionol, bithionol sulfoxide and menichlopholan; various salicylanilide compounds including tribromsalan, oxyclozanide, clioxanide, rafoxanide, brotianide, bromoxanide and closantel; triclabendazole, diamfenetide, clorsulon, hetolin and emetine.
  • Anticestodal compounds may also be advantageously used in the compositions of the invention including, but not limited to, arecoline in various salt forms, bunamidine, niclosamide, nitroscanate, paromomycin and paromomycin II.
  • compositions of the invention may include other active agents that are effective against artropod parasites.
  • Suitable active agents include, but are not limited to, bromocyclen, chlordane, DDT, endosulfan, lindane, methoxychlor, toxaphene, bromophos, bromophos-ethyl, carbophenothion, chlorfenvinphos, chlorpyrifos, crotoxyphos, cythioate, diazinon, dichlorenthion,, diemthoate, dioxathion, ethion, famphur, fenitrothion, fenthion, fospirate, iodofenphos, malathion, naled, phosalone, phosmet, phoxim, propetamphos, ronnel, stirofos, allethrin, cyhalothrin, cypermethrin, deltame
  • An antiparasitic agent that can be combined with the compound of the invention to form a composition can be a biologically active peptide or protein including, but not limited to, depsipeptides, which act at the neuromuscular junction by stimulating presynaptic receptors belonging to the secretin receptor family resulting in the paralysis and death of parasites.
  • the depsipeptide is emodepside (see Willson et al., Parasitology, Jan. 2003, 126(Pt l):79-86).
  • an insecticidal agent that can be combined with the compound of the invention to form a composition can be a substituted pyridylmethyl derivative compound such as imidacloprid. Agents of this class are described above, and for example, in U.S. Patent No. 4,742,060 or in EP 0 892 060. It would be well within the skill level of the practitioner to decide which individual compound can be used in the inventive formulation to treat a particular infection of an insect.
  • an insecticidal agent that can be combined with the compositions of the invention is a semicarbazone, such as metaflumizone.
  • compositions of the invention may advantageously include one or more compounds of the isoxazoline class of compounds.
  • active agents are described in WO 2007/079162, WO 2007/075459 and US 2009/0133319, WO 2007/070606 and US 2009/0143410, WO 2009/003075, WO 2009/002809, WO 2009/024541, WO 2005/085216 and US 2007/0066617 and WO 2008/122375, all of which are incorporated herein by reference in their entirety.
  • nodulisporic acid and its derivatives may be added to the compositions of the invention.
  • These compounds are used to treat or prevent infections in humans and animals and are described, for example, in U.S. Patent No. 5,399,582, 5,962,499, 6,221,894 and 6,399,786, all of which are hereby incorporated by reference in their entirety.
  • the compositions may include one or more of the known nodulisporic acid derivatives in the art, including all stereoisomers, such as those described in the literature cited above.
  • anthelmintic compounds of the amino acetonitrile class (AAD) of compounds such as monepantel (ZOLVIX) and the like may be added to the compositions of the invention.
  • AAD amino acetonitrile class
  • ZOLVIX monepantel
  • the compositions of the invention may also include aryloazol-2-yl cyanoethylamino compounds such as those described in US 2008/0312272 to Soil et al., which is incorporated herein in its entirety, and thioamide derivatives of these compounds, as described in U.S.
  • compositions of the invention may also be combined with paraherquamide compounds and derivatives of these compounds, including derquantel (see Ostlind et al., Research in Veterinary Science, 1990, 48, 260-61; and Ostlind et al., Medical and Veterinary Entomology, 1997, 11, 407-408).
  • the paraherquamide family of compounds are known class of compounds that include a spirodioxepino indole core with activity against certain parasites (see Tet. Lett. 1981, 22, 135; /. Antibiotics 1990, 43, 1380, and /. Antibiotics 1991, 44, 492).
  • marcfortines A- C are also known and may be combined with the formulations of the invention (see J. Chem. Soc. - Chem. Comm. 1980, 601 and Tet. Lett. 1981, 22, 1977). Further references to the paraherquamide derivatives can be found, for example, in WO 91/09961, WO 92/22555, WO 97/03988, WO 01/076370, WO 09/004432, U.S. Patent 5,703,078 and U.S. Patent 5,750,695, all of which are hereby incorporated by reference in their entirety.
  • the additional active agent is included in a dose of between about 0.1 ⁇ g and about 1000 mg. More typically, the additional active agent may be included in a dose of about 10 ⁇ g to about 500 mg, about 1 mg to about 300 mg, about 10 mg to about 200 mg or about 10 mg to about 100 mg. In one embodiment of the invention, the additional active agent is included in a dose of between about 1 ⁇ g and about 10 mg. In other embodiments of the invention, the additional active agent may be included in a dose of about 5 ⁇ g/kg to about
  • the additional active agent may be present in a dose of about 0.01 mg/kg to about 30 mg/kg, about 0.1 mg/kg to about 20 mg/kg, or about 0.1 mg/kg to about 10 mg/kg of weight of animal. In other embodiments, the additional active agent may be present in a dose of about 5 ⁇ g/kg to about 200 ⁇ g/kg or about 0.1 mg/kg to about 1 mg/kg of weight of animal. In still another embodiment of the invention, the additional active agent is included in a dose between about 0.5 mg/kg to about 50 mg/kg.
  • the proportions, by weight, of the combinations of N-aryl-pyrazole compound/formamidine compound and the additional active agent are for example between about 1/10,000 and about 10,000/1. More typically, the proportions are in a proportion by weight of about 1/100 to about 10,000/1, about 1/1 to about 10,00/1, or about 5/1 to about 10,000/1, or about preferably about 5/1 to about 1000/1.
  • one of ordinary skill in the art would be able to select the appropriate ratio of N-aryl-pyrazole compound/formamidine compound and the additional active agent for the intended host and use thereof.
  • a fragrance may be added to any of the compositions of the invention.
  • Fragrances which are useful for the invention include but are not limited to:
  • carboxylic acid esters such as octyl acetate, isoamyl acetate, isopropyl acetate and isobutyl acetate;
  • fragrance oils such as lavender oil.
  • compositions of the invention are made by mixing the appropriate amount of N- aryl-pyrazole compound and formamidine compound, veterinarily acceptable solvent and optionally a crystallization inhibitor, film former, odor dissipation enhancer, etc., to form a composition of the invention.
  • Various forms e.g. tablets, pastes, pour-on, spot-on, collars, etc.
  • of the composition can be obtained by following the method of making these forms described above by the description of making these forms found in general formulation text known to those in the art, e.g.
  • the inventive formulations may contain other inert ingredients such as antioxidants, preservatives, or pH stabilizers. These compounds are well known in the formulation art.
  • Antioxidant such as an alpha tocopherol, ascorbic acid, ascrobyl palmitate, fumaric acid, malic acid, sodium ascorbate, sodium metabisulfate, n-propyl gallate, BHA (butylated hydroxy anisole), BHT (butylated hydroxy toluene) monothioglycerol and the like, may be added to the present formulation.
  • the antioxidants are generally added to the formulation in amounts of from about 0.01 to about 2.0%, based upon total weight of the formulation, with about 0.05 to about 1.0% being especially preferred.
  • Preservatives such as the parabens (methylparaben and/or propylparaben), are suitably used in the formulation in amounts ranging from about 0.01 to about 2.0%, with about 0.05 to about 1.0% being especially preferred.
  • Other preservatives include benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butylparaben, cetrimide, chlorhexidine, chlorobutanol, chlorocresol, cresol, ethylparaben, imidurea, methylparaben, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, thimerosal, and the like. Preferred ranges for these compounds include from about 0.01 to about 5%.
  • Buffering systems include, for example, systems selected from the group consisting of acetic acid/acetate, malic acid/malate, citric acid/citrate, tataric acid/tartrate, lactic acid/lactate, phosphoric acid/phosphate, glycine/glycimate, tris, glutamic acid/glutamates and sodium carbonate.
  • compositions of the invention are administered in anti-parasiticidally effective amounts which are determined by the route of administration, e.g. oral, parenteral, topical, etc.
  • the compositions of the invention are applied as a pour-on or spot-on formulation.
  • the compounds and compositions of the invention can be applied against a single pest or combinations thereof.
  • the compositions of the invention that contain 1-arylpyrazole compounds, optionally in combination with a formamidine compound, may be administered continuously, for treatment or prevention, by known methods. In this manner, an effective amount of the compounds is administered to the animal in need thereof.
  • effective amount is intended a sufficient amount of a composition of the invention to eradicate or reduce the number of parasites infesting the animal.
  • a dose of from about 0.001 to about 100 mg per kg of body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but, of course, there can be instances where higher or lower dosage ranges are indicated, and such are within the scope of this invention. It is well within the routine skill of the practitioner to determine a particular dosing regimen for a specific host and parasite.
  • the treatment is carried out so as to administer to the animal, on a single occasion, a dose containing between about 0.001 and about 100 mg/kg of a 1-arylpyrazole compound.
  • the treatment is via a direct topical administration such as a pour-on, ready-to-use, spot-on, spray, etc. type formulation. Higher amounts may be provided for very prolonged release in or on the body of the animal.
  • the amount of 1-arylpyrazole compound for birds and other animals which are small in size is greater than about 0.01 mg/kg, and in another embodiment for the treatment of small-sized birds and other animals, the amount of l-aryl-5- alkyl pyrazole compound is between about 1 and about 100 mg/kg of weight of animal.
  • the solutions according to the invention may be applied using any means known per se, e.g. using an applicator gun or a metering flask.
  • the volume applied can be of the order of about 0.3 to about 100 mL. In other embodiments, volume applied of the pour-on formulations may be about 1 ml to about 100 ml or about 1 ml to about 50 ml. In still other embodiments, the volume may be about 5 ml to about 50 ml or about 10 ml to about 100 ml.
  • application of a spot-on formulation according to the present invention can also provide long-lasting and broad-spectrum efficacy when the solution is applied to the mammal or bird.
  • the spot-on formulations provide for topical administration of a concentrated solution, suspension, microemulsion or emulsion for intermittent application to a spot on the animal, generally between the two shoulders (solution of spot-on type).
  • an N-aryl-pyrazole compound and a formamidine compound can be administered together from separate compartments of a dual-cavity container.
  • an N-aryl-pyrazole compound and a formamidine compound can be combined in the same solvent system.
  • N-aryl-pyrazole compound and a formamidine compound would be expected to have efficacy against a wide range of parasites including fleas, ticks and mites. It was surprising that the application of a 1-arylpyrazole compound and a formamidine compound, whether applied from the same solvent system or from different solvent systems, resulted in synergistic effects with respect to efficacy against fleas and ticks. It was also surprising that a 1-arylpyrazole compound and a formamidine compound could be combined, since it has been observed that formamidine compounds may degrade in the presence of 1-arylpyrazole compounds.
  • a composition comprising a 1-arylpyrazole compound and a formamidine compound has an efficacy against ticks of about 80.0% or higher for at least about 37 days.
  • a composition comprising a 1-arylpyrazole compound and a formamidine compound has an efficacy against ticks of about 90.0% or higher for at least about 37 days.
  • a composition comprising a 1-arylpyrazole compound and a formamidine compound has an efficacy of about 95% or higher for about 37 days or longer, about 44 days or longer, about 51 days or longer or for about 58 days or longer.
  • a composition comprising a 1-arylpyrazole compound and a formamidine compound has an efficacy of about 99% or higher for about 51 days or longer or for about 58 days or longer.
  • a further embodiment of the invention is where the 1-arylpyrazole compound is fipronil; the formamidine compound is amitraz.
  • the 1-arylpyrazole compound is a 5-alkyl substituted 1-arylpyrazole compound and the formamidine compound is amitraz.
  • a composition comprising a 1- arylpyrazole compound and a formamidine compound has an efficacy against fleas of about 98.5% or higher for about 37 days or longer.
  • a composition comprising a 1-arylpyrazole compound and a formamidine compound has an efficacy against ticks of about 98.5% or higher for about 37 days or longer or about 44 days or longer.
  • a composition comprising a 1- aryl-pyrazole compound and a formamidine compound has an efficacy against ticks of about 95.0% or higher for about 51 days or longer.
  • a composition comprising a 1-arylpyrazole compound and a formamidine compound has an efficacy of about 99% or higher for about 58 days or longer.
  • a further embodiment of the invention is where the 1-arylpyrazole compound is fipronil; the formamidine compound is amitraz.
  • the 1-arylpyrazole compound is a 5-alkyl substituted 1-arylpyrazole compound and the formamidine compound is amitraz.
  • compositions of the embodiments either applied from the same solvent system or applied from different solvent systems for each 1-arylpyrazole and for a formamidine make them suitable for once a month (30 days or a calendar month) or once very two months (60 days or two calendar months) application of the composition in its deliverable form.
  • the animals that can be treated with the compositions of the invention include but are not limited to birds and mammals (either wild or domesticated), e.g., livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle.
  • livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle.
  • the mammal is a cat or a dog.
  • a single formulation containing the active agent in a substantially liquid carrier and in a form which makes possible a single application, or an application repeated a small number of times will be administered to the animal over a localized region of the animal, e.g. between the two shoulders.
  • the localized region has a surface area of about 10 cm or larger.
  • the localized region has a surface are of between about 5 and about 10 cm 2 area.
  • Example 1 Stability of 1-Arylpyrazole Formulations
  • Compound 1 (3-cyano-l-(2-chloro-6-fluoro-4-trifluoromethylphenyl)- 4- dichlorofluoromethylsulfinyl-5-methyl-lH-pyrazole) was dissolved in a solvent or a combination of two or more solvents at 10% w/w.
  • the formulations thus prepared were analyzed, using ⁇ PLC, for the content of compound 1 as the initial timepoint reading.
  • Dogs were infested with approximately 50 ticks (Rhipicephalus sanguineus) on days -1, 7, 14, 21, 28, 35 and 42. Dogs were also infested with approximately 100 fleas (Ctenocephalides felis) on days -1, 8, 15, 22, 29, 36, and 43. Treatment was applied by parting the hair and applying the formulation directly onto the skin on one spot at the midline of the neck, between the base of the skull and the shoulder blades. The dose rate of each of the topical solutions was 0.1 ml/kg (10 mg/kg) body weight.
  • Table 2 The efficacy of compound 1 in various formulations is shown Table 2 below. Duration of flea and tick efficacy is shown in Tables 3 and 4 below. As can be seen from the tables below, formulations comprising Compound 1 in triacetin formulations provide improved efficacy against flees and ticks in this study.
  • Treatment groups in Table 3 were treated with the drug, dosage and solvent formulations as indicated in Table 2.
  • Table 4. Duration of Tick Efficacy of Compound 1 in Various Formulations. (% efficacy against ticks measured 24 hours after each weekly infestation)
  • Treatment groups in Table 4 were treated with the drug, dosage and solvent formulations as indicated in Table 2. Negative values indicate % increase in tick counts relative to control.
  • a separate clinical efficacy study in dogs was designed with an untreated control group and 5 test groups treated with compound 1. Each group had six dogs.
  • Test articles were formulated as topical spot-on solutions containing compound 1, 10-20% w/v in a solvent or a combination of solvents as described above. Dogs were infested with approximately 50 ticks (Rhipicephalus sanguineus) on days -1, 7, 14, 21, 28, 35 and 42. Dogs were also infested with approximately 100 fleas (Ctenocephalides felis) on days -1, 8, 15, 22, 29, 36, and 43. Treatment was applied by parting the hair and applying the formulation directly onto the skin on one spot at the midline of the neck, between the base of the skull and the shoulder blades.
  • the dose rate of each of the topical solutions was 0.1 ml/kg (10 mg/kg) body weight except for treatment group 4, which received 0.2 ml/kg (20 mg/kg).
  • the efficacy of compound 1 is shown in Table 5 below. Duration of flea and tick efficacy is shown in Tables 6 and 7 below. As can be seen from the table, transcutol renders compound 1 superior efficacy. It should be noted that Study A and Study B were conducted at different times and locations, and the results of each clinical study may differ from the other based on various environmental factors. Thus, the results of one clinical study should not be compared with those of another due to these factors. Table 5. Flea and Tick Efficac of Com ound 1 in Various Formulations.
  • Treatment groups in Table 6 were treated with the drug, dosage and solvent formulations as indicated in Table 5.
  • Treatment Groups were: Treatment Group 2: fipronil at 0.1 mL/kg body weight (10 mg/kg); Treatment Group 3: Compound 1 at 0.1 mL/kg (10 mg/kg) body weight; Treatment Group 4: Compound 1 at 0.2 mL/kg (20 mg/kg) body weight; Treatment Group 5: Compound 1 at 0.1 mL/kg (10 mg/kg) body weight plus amitraz at 0.04 mL/kg (8 mg/kg) body weight; Treatment Group 6: fipronil at 0.1 mL/kg (10 mg/kg) body weight plus amitraz at 0.04 mL/kg (8 mg/kg) body weight.
  • Treatment was applied by parting the hair and applying the formulation(s) directly onto the skin on one spot at the midline of the neck, except for Groups 4, 5 and 6 which were applied in approximately equal volumes on two spots, one spot between the base of the skull and the shoulder blades and the other at the front of the shoulder blades. All dogs were infested with approximately 50 Rhipicephalus sanguineus ticks on
  • Tables 8 and 9 below show the % efficacy of formulations comprising fipronil at 0.1 ml/kg of body weight, Compound 1 at 10 ml/kg and 20 ml/kg, and fipronil and Compound 1 both at 10 ml/kg in combination with amitraz at 0.04 ml/kg of body weight compared to control group without active compounds.
  • the percent reduction in flea counts of the treated groups with respect to the Control group over the study is shown in Figure 14.
  • Treatment Group 2 fipronil 10 mg/kg; Group 3: Cmpd 1 10 mg /kg; Group 4: Cmpd 1 20 mg /kg; Group 5: Cmpd 1 (10 mg /kg) + amitraz (8 mg /kg); Group 6: fipronil (10 mg /kg) + amitraz (8 mg /kg)
  • a fourth clinical study was conducted to determine the efficacy of topically administered Compound 1 and fipronil against induced infections of Ctenocephalides felis in cats. Twenty four cats (17 males, 7 females) were included in the study. Six replicates of four cats each were formed based on decreasing Day -5 flea counts. Within replicates, cats were randomly allocated to Treatment Groups 1, 2, 3 or 4, respectively, by using a die: Group 1 - untreated (vehicle control); Group 2 - Compound 1 (10 mg/kg); Group 3 - Compound 1 (20 mg/kg); Group 4 - fipronil (10 mg/kg). Treatment was performed by topical administration of the formulations in the midline of the neck, between the base of the skull and the shoulder blades in a single spot after parting the hair. Animals were observed hourly for approximately four hours following treatment.
  • the cats were infested with approximately 100 Ct. felis fleas each during acclimation on Day -6 for allocation purposes, and on Days -1, 14, 21, 28, 35 and 42 for treatment efficacy evaluation purposes.
  • the fleas were removed by combing each cat approximately 24 hours following each infestation except for the Day -1 infestation which was followed by flea removal and count on Day 1 (-48 hours following infestation).
  • Table 10 shows the % efficacy of each treatment group compared to the control group.
  • Table 10 Duration of Flea Efficacy of Compound 1 and Fipronil (% efficacy against fleas measured 24 hours after each weekly infestation)
  • Treatment Group 2 Cmpd 1 10 mg/kg; Group 3: Cmpd 1 20 mg /kg; Group 5: fipronil (10 mg /kg)
  • Anisole was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Amitraz was added to the anisole solution with stirring and the stirring was continued until the amitraz was fully dissolved. The volume was adjusted to 100% with anisole.
  • Butyl acetate was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Amitraz was added to the butyl acetate solution with stirring and the stirring was continued until the amitraz was fully dissolved. The volume was adjusted to 100% with butyl acetate.
  • Ethyl benzoate was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Amitraz was added to the ethyl benzoate solution with stirring and the stirring was continued until the amitraz was fully dissolved. The volume was adjusted to 100% with ethyl benzoate.
  • Benzyl benzoate was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Amitraz was added to the benzyl benzoate solution with stirring and the stirring was continued until the amitraz is fully dissolved. The volume was adjusted to 100% with benzyl benzoate.
  • Butyl acetate was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Anisole was added to the butyl acetate solution and mixed. Amitraz was then added to the anisole/butyl acetate solution with stirring and the stirring was continued until the amitraz is fully dissolved. The volume was adjusted to 100% with butyl acetate.
  • Butyl acetate was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Methyl isobutyl ketone was added to the butyl acetate solution and mixed. Amitraz was then added to the methyl isobutyl ketone/butyl acetate solution with stirring and the stirring was continued until the amitraz was fully dissolved. The volume was adjusted to 100% with butyl acetate.
  • Butyl acetate was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Benzyl benzoate was added to the butyl acetate solution and mixed. Amitraz was then added to the benzyl benzoate/butyl acetate solution with stirring and the stirring was continued until the amitraz was fully dissolved. The volume was adjusted to 100% with butyl acetate.
  • Butyl acetate was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Ethyl benzoate was added to the butyl acetate solution and mixed. Amitraz was then added to the ethyl benzoate/butyl acetate solution with stirring and the stirring was continued until the amitraz was fully dissolved. The volume was adjusted to 100% with butyl acetate.
  • Butyl acetate was added in the amount of about 50% of the volume to be prepared into a flask with a stopper. Benzyl acetate was added to the butyl acetate solution and mixed. Amitraz was then added to the benzyl acetate/butyl acetate solution with stirring and the stirring was continued until the amitraz was fully dissolved. The volume was adjusted to 100% with butyl acetate.
  • Formulation comprising amitraz in anisole (formulation L), butyl acetate (formulation M), methyl isobutyl ketone and ethyl benzoate were evaluated for stability by HPLC, similarly to the stability study for formulations comprising compound 1.
  • the formulations were tested for initial concentration of amitraz % (w/v) and aged at 50 0 C for three months.
  • the concentration of amitraz in each formulation was determined at 1 month, 2 months and 3 months to determine the stability of amitraz in each formulation.
  • Table 11 formulations of amitraz in anisole, butyl acetate and methyl isobutyl ketone do not show degradation at these conditions.
  • Amitraz solutions in a single solvent exhibited an unpleasant smell that lasted from about 30 minutes to about 90 minutes when applied to filter paper. However, when the solutions of Formulations P and Q were applied to filter paper, the smell disappeared after only about 10 to about 15 minutes.
  • a fipronil formulation (commercial product) was prepared and stored separately from amitraz. Amitraz was was formulated with the same carrier. Both parts, fipronil and amitraz in solvent(s) were stored separately and applied simultaneously. Amounts applied were calculated to keep dose at 10% (w/v) each in final formulation and 10 mg/kg BW of actives in amount applied.
  • Table 13 below shows the percent efficacy after topical application of the formulations comprising amitraz alone, fipronil alone or amitraz and fipronil to dogs. In brief, treatment was applied by parting the hair on the midline of the neck, between the base of the skull and the shoulder blades, and applying the formulation directly onto the skin. Table 13. Efficacy of Compositions Comprising Amitraz and Fipronil against Ticks
  • Example 10 The amitraz and fipronil composition described in Example 10 were used in this study. Table 14 below shows the percent efficacy after topical application of the formulation to dogs. Treatment was applied by parting the hair on the midline of the neck, between the base of the skull and the shoulder blades, and applying the formulation directly onto the skin.
  • Fipronil was dissolved in acetone containing 0.019% of a mixture of Tritonl52 and Triton 172 (1:3, v/v) and 0.4% DMSO to achieve the desired concentration. Dosages were serially diluted using this same formulation. For treatments containing amitraz, amitraz was added to the above solution to achieve the desired concentration. 0.5ml of the solution was used to treat 20ml scintillation vials containing a 0.125" hole in the cap. This was achieved by rolling the uncapped vials until the acetone had evaporated thus leaving the walls of the vial coated with the experimental compound(s). Filter papers treated with this same solution were placed in the cap and bottom of the treated vial.
  • Vials were capped and held over night at 24°C and 95%RH after which 10 adult Rhipicephalus sanguineus ticks were placed into each vial. The vials were held under the same conditions mentioned above for the duration of the test. The number of living and dead ticks in each vial was determined at 6, 24 and 48hrs. Tables 15 and 16 below show the efficacy of fipronil alone and fipronil in combination with amitraz at various concentrations. Table 17 presents synergistic ratios of amitraz and fipronil and shows the calculated EC50 and EC90 values at 6 hours, 24 hours and 48 hours for fipronil alone and the combination of fipronil and amitraz.
  • Rate is the ppm of the solution used to treat the vials.
  • Rate is the ppm of the solution used to treat the vials. Table 17. EC50, EC90 and Synergistic Ratios of Tick Efficacy of Fipronil with Amitraz in DMSO Contact Test
  • Synergistic ratio is EC50 or EC90 alone divided by EC50 or EC90 with Amitraz.
  • Rate is the ppm of the solution used to treat the vials. Table 19. Synergistic Tick Efficacy of Fipronil with Different Dosages of Amitraz in DMSO Contact Test
  • Table 20 shows the calculated EC50 and EC90 values for this study for fipronil alone and three different combinations of fipronil with amitraz. As the table shows, combinations of fipronil with amitraz are significantly more potent than fipronil alone even just 4 hours after administration. Table 20. EC50, EC90 and Synergistic Ratios of Fipronil with Different Dosages of Amitraz in Tick Contact Test
  • Synergistic ratio is EC50 or EC90 alone divided by EC50 or EC90 with Amitraz.
  • Example 14 Tick Motility of Synergistic Formulations Comprising Amitraz and
  • the synergistic efficacy of combinations of fipronil and amitraz was demonstrated by measuring the motility of ticks exposed to an environment containing different amounts of fipronil alone, amitraz alone or combinations of fipronil and amitraz.
  • An imaging system was used for the automated analysis of tick motility in response to amitraz and fipronil treatments to remove the subjective interpretation of manual test evaluation.
  • the study was designed to evaluate the affect of amitraz and fipronil alone and in combination, as compared to a control, on the motility of ticks over time.
  • the motility of adult Rhipicephalus sanguineus was compared for amitraz-only, fipronil-only and the combination of fipronil and amitraz in a petri dish assay using the imaging system.
  • the assay was run using a fixed dilution of amitraz (0.32ug/cm 2 ), with serial dilutions of fipronil (1.3, 0.33, 0.08, 0.02, or 0.005 ug/cm 2 ) alone and in combination with the fixed dilution of amitraz.
  • Six independent replications were conducted.
  • a plate holding four petri dishes was custom made for the imaging system. At each time point the plate holding four petri dishes was placed on the imaging system and evaluated for motility. The set up of the plate for each evaluation is illustrated below in Table 21. Table 21. Tick Motility Set Up
  • Dish Al a volume of 625 ⁇ L of ethanol was used to treat the tops and 625 ⁇ L to treat the bottoms of the petri dish. All solutions were formulated in 100% ethanol.
  • a volume of 125 ⁇ L of the 25 ppm amitraz solution was used to treat the tops and 125 ⁇ L to treat the bottoms of the petri dish.
  • the top and bottom portions of the petri dishes were each treated with 500 ⁇ L of the 25 ppm solution of fipronil (serially diluted for each Plate 1-5) and 125 ⁇ L of the 25 ppm solution of amitraz.
  • each of the top and bottom portions of the petri dishes were treated with 500 ⁇ L of the 25 ppm solution of fipronil (serially diluted for each Plate 1-5).
  • the petri dishes were left open under a fan and allowed to dry for 1 hour.
  • the dishes were infested with 10 adult Rhipicephalus sanguineus (supplied by Ecto Services, Inc. Henderson, NC). The ticks were left undisturbed for 1 hour before evaluation in the imaging system. Between evaluations ticks were maintained at approximately 21 °C and 60% RH.
  • each Plate 1-5 was sequentially placed into the imaging system for evaluation.
  • Image processing calculates the change in movement of the ticks between each image. The value generated is equal to the movement in each petri dish during the image time.
  • the ticks in each individual petri dish were then stimulated to move by breathing/exhaling into the plate.
  • the plates were placed back into the imaging system for another evaluation to determine if the treatment affected the tick's ability to move.
  • Image capture was repeated as in the pre- stimulated evaluation. Evaluations were made at 1, 4, 18, and 24 hours post infest (hpi) for 3 trials. For 3 trials the 4 hour evaluation was not done and for 3 trials the third evaluation was done at 21 to 22 hours.
  • Raw data values were exported from the imaging system and comparative analysis of treatments over time was conducted. The geometric means of the movement values for stimulated ticks from all time points are shown in Table 22.
  • Table 22 Geometric Means of movement values for stimulated ticks at all time points.
  • Example 15 Tick Efficacy of Synergistic Formulations Comprising Amitraz and Compound 1 - Tick DMSO Contact Assay
  • Scintillation vials were treated with commercial and experimental compounds using the same procedure described in Example 12 above.
  • the treated vials were used to determine the contact toxicity of compounds against adult brown dog ticks (Rhipicephalus sanguineus).
  • the ticks were supplied by Ecto Services Inc. Henderson, NC.
  • Rate is the ppm of the solution used to treat the vials.
  • Table 25 EC50, EC90 and Synergistic Ratios of Tick Efficacy Formulations of Compound 1 with Amitraz in DMSO Contact Test.
  • Synergistic ratio is EC50 or EC90 alone divided by EC50 or EC90 with Amitraz.
  • Example 16 provides data showing unexpected and improved efficacy of compound 1 with low concentrations of Amitraz.
  • the EC90 values are substantially improved using compound 1.
  • Example 16 Tick Efficacy of Synergistic Formulations with Reduced Dosages of Acaricide - Tick DMSO Contact Assay
  • the assay protocol was similar to the protocol of Example 15, with the following exceptions: 1) The vials were visually evaluated at 4, 24 and 48 hours post infestation for living / dead ticks and percent mortality was determined, and 2) the acaricide (amitraz) was added at dosages of 12.5 ppm, 6.25 ppm, and 3.13 ppm.
  • Rate is the ppm of the solution used to treat the vials.
  • Rate is the ppm of the solution used to treat the vials.
  • Table 28 EC50, EC90 and Synergistic Ratios of Tick Efficacy Formulations of Compound 1 with Different Dosages of Amitraz in DMSO Contact Test.
  • Synergistic ratio is EC50 or EC90 alone divided by EC50 or EC90 with Amitraz.
  • One means for topically delivering the inventive combination of active ingredients such as those described in Examples above is to utilize a dual cavity container.
  • the first cavity of the dual- cavity container contains a clear colorless/light yellow composition comprising of amitraz and octyl benzoate as a solvent.
  • This composition may also comprise 2,4-dimethylaniline, formamidine-2', 4'- xylidide,N-methyl-N'-(2,4-xylyl) formamidine, and/or N,N'-bis (2,4-xylyl) formamidine; for example, in amounts ranging from about 0.1% to about 8% of the 20% w/v.
  • water may be present; for example, in an amount of up to about 0.06% w/w.
  • water may be present, for example, in an amount of up to about 0.4% w/w.
  • the composition may also have a maximum acid value of about 0.14.
  • This composition may also include the antioxidants BHA and BHT.
  • the amount of BHA if present ranges from 0.016 - 0.022% w/v and the amount for BHT if present ranges from 0.008 - 0.011% w/v.
  • water may be present in an amount of up to 1.5% w/w. In another embodiment of this composition, water may be present in an amount of up to 10% w/w.
  • the first cavity of the dual-cavity container contains a clear colorless/light yellow composition comprising of amitraz and octyl benzoate as a solvent.
  • This composition may also comprise 2,4-dimethylaniline, formamidine-2', 4'- xylidide,N-methyl-N'-(2,4-xylyl) formamidine, and/or N,N'-bis (2,4-xylyl) formamidine; for example, in amounts ranging from about 0.1% to about 8% of the 20% w/v.
  • water may be present; for example, in an amount of up to about 0.06% w/w.
  • water may be present, for example, in an amount of up to about 0.4% w/w.
  • the composition may also have a maximum acid value of about 0.14.
  • This composition may also include the antioxidants BHA and BHT.
  • the amount of BHA if present ranges from 0.001 - 0.03% w/v and the amount for BHT if present ranges from 0.002 - 0.018% w/v.
  • water may be present in an amount of up to 1.5% w/w. In another embodiment of this composition, water may be present in an amount of up to 10% w/w.
  • a veterinary formulation for treating or preventing a parasitic infestation in an animal comprising: (a) a l-aryl-5-alkyl or 5-haloalkylpyrazole of formula (IA) or a veterinarily acceptable salt thereof,
  • R 2a is -S(O) 1n R 1 la ;
  • R 3a is methyl, ethyl or C 1 -C 4 haloalkyl;
  • R 4a is halogen;
  • R ⁇ a is C 1 -C 4 alkyl or haloalkyl;
  • R 13a is halogen;
  • Riia is C 1 -C 4 haloalkyl; and
  • m is 0, 1 or 2;
  • a composition for the treatment or prevention of a parasitic infestation in an animal comprising at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier, at least one formamidine compound in a second veterinarily acceptable carrier, and optionally at least one crystallization inhibitor(s), wherein the 1-arylpyrazole compound(s) and first veterinarily acceptable carrier are isolated and not in fluid communication with the formamidine compound(s) and the second veterinarily acceptable carrier.
  • composition of paragraph 2 wherein the one or more 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are in one cavity of a dual-cavity container and the one or more formamidine compound(s) and the second veterinarily acceptable carrier are in a second cavity of a dual-cavity container, wherein the first cavity is defined by a front wall and a divider wall; and the second cavity is defined by a rear wall and the divider wall.
  • composition of paragraph 2 or 3, wherein the at least one 1-arylpyrazole compounds has formula (IB): b
  • Ri b is alkyl, CN or halogen;
  • R 2 b is S(O) n Ri4b or 4,5-dicyanoimidazol-2-yl or haloalkyl;
  • Ri 4b is alkyl or haloalkyl
  • R ⁇ b is a halogen, haloalkyl, haloalkoxy, S(O) q CF 3 or SF 5 group;
  • R 7B and R 8B independently represent a hydrogen, alkyl, haloalkyl, -C(O)alkyl, -S(O) 1 CF 3 , acyl or alkoxycarbonyl; or
  • R 7b and R 8b can together form a divalent alkylene radical which is optionally interrupted by one or two divalent heteroatoms;
  • R % is an alkyl or haloalkyl
  • Rio b is hydrogen, alkyl or haloalkyl
  • Ru b is hydrogen or alkyl radical
  • Ri 2b is an optionally substituted aryl or an optionally substituted heteroaryl group
  • R 4 b and Ri 3 b represent, independently of one another, hydrogen, halogen CN or NO 2 ; m, n, q and r represent, independently of one another, an integer equal to 0, 1 or 2; and Z represents a trivalent nitrogen atom or a C-Ri 3b radical, the three other valencies of the carbon atom forming part of the aromatic ring.
  • Ri 4b is Ci-Ce-alkyl or C r C 6 -haloalkyl; R 3 b is -NR 7 bRsb,
  • R 7b and Rg b independently represent a hydrogen, Ci-C ⁇ -alkyl, Ci-C ⁇ -haloalkyl, - C(O)C r C 6 -alkyl, -S(O) 1 CF 3 , C r C 6 -acyl or C r C 6 -alkoxycarbonyl radical;
  • R 6b is a halogen, Ci-C ⁇ -haloalkyl, or Ci-C ⁇ -haloalkoxy;
  • m, n, q and r represent, independently of one another, an integer equal to 0 or 1 ; and Z is a C-Ri3b radical.
  • Ri 4b is Ci-C ⁇ -alkyl or Ci-C ⁇ -haloalkyl
  • R 3b is alkyl or haloalkyl
  • R 6b is a halogen, Ci-C ⁇ -haloalkyl, or Ci-C ⁇ -haloalkoxy; m, n, q and r represent, independently of one another, an integer equal to 0 or 1 ; and Z is a C-Ri3b radical.
  • the first veterinarily acceptable carrier comprises acetone, acetonitrile, benzyl alcohol, ethanol, isopropanol, diisobutyl adipate, diisopropyl adipate, butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, liquid polyoxyethylene glycols, propylene glycol monomethyl ether, propylene glycol monoethyl ether, 2-pyrrolidone, N-methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, octyl acetate, propylene carbonate, butylene carbonate, dimethyl sulfoxide, an amide, dimethylformamide, dimethylacetamide, or any combination thereof.
  • the second veterinarily acceptable carrier comprises aryl ethers, alkoxybenzene compounds; aliphatic carboxylic acid esters, aromatic carboxylic acid esters, aliphatic ketones, cyclic ketones, or mixtures thereof.
  • the second veterinarily acceptable carrier comprises methoxybenzene, butyl acetate, benzyl acetate, methyl isobutyl ketone, ethyl benzoate, benzyl benzoate, octyl acetate, or mixtures thereof.
  • composition of paragraph 2 wherein the second veterinarily acceptable carrier comprises an aprotic solvent with a dielectric constant of about 2 to about 30.
  • composition for the treatment and prevention of a parasitic infestation in an animal comprising at least one formamidine compound(s), at least one 1-arylpyrazole compound(s) of formula (IA), or veterinarily acceptable salts thereof,
  • R 3 a is methyl, ethyl or C 1 -C 4 haloalkyl
  • R4a is halogen
  • R ⁇ a is Ci -C 4 alkyl or haloalkyl
  • Rl3a is halogen
  • RlIa is C 1 -C 4 haloalkyl; and m is 0, 1 or 2; at least one veterinarily acceptable carriers; and optionally a crystallization inhibitor.
  • x is an integer from 0-5;
  • Ri 5 is hydrogen or alkyl
  • Ri 6 is hydrogen or alkyl
  • Rn is hydrogen, alkyl or
  • composition of paragraph 2 or 11, wherein the at least one formamidine compound comprises amitraz, formetanate, chloromebuform, formparanate or chlodimeform.
  • composition of paragraph 2 or 11 wherein the at least one 1-arylpyrazole compound(s) is combined with a first veterinarily acceptable carrier and the at least one formamidine compounds is combined with a second veterinarily acceptable carrier; and wherein the 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are compartmentalized together and not in fluid communication with, the at least one formamidine compound(s) and the second veterinarily acceptable carrier.
  • a composition for the treatment and prevention of a parasitic infestation in an animal comprising at least one formamidine compound and at least one aprotic solvent(s) with a dielectric constant of about 2 to about 30, wherein the composition is stable for at least 24 months at 25° C.
  • the at least one aprotic solvent(s) with a dielectric constant of about 2 to about 30 is a C 1 -C 1O carboxylic acid ester, a phenyl carboxylic acid ester, a carboxylic acid benzyl ester, a benzoic acid Ci -C 4 alkyl ester, a Ci-C 6 saturated aliphatic ketone, or a mixture thereof.
  • composition of paragraph 15 comprising two or more aprotic solvents with a dielectric constant of about 2 to about 30, wherein a dissipation of an unpleasant odor from the composition occurs within about 5 minutes to within about 25 minutes after application.
  • a method for the treatment or prevention of a parasitic infestation in an animal comprising administering an effective amount of the composition of paragraph 2 or 11 to the animal in need thereof.
  • composition is administered using a dual- cavity container, wherein the 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are administered from a first cavity of the dual cavity container and the formamidine compound(s) and the second veterinarily acceptable carrier are administered from a second cavity of the dual cavity container.
  • a method for the treatment or prevention of a parasitic infestation in an animal comprising administering an effective amount of the composition of paragraph 11 to the animal in need thereof.
  • a method for the treatment or prevention of a parasitic infestation in an animal comprising administering to the animal an effective amount of a composition comprising at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier and at least one formamidine compound in a second veterinarily acceptable carrier from a dual-cavity container; wherein the at least one 1-arylpyrazole compound(s) and the first veterinarily acceptable carrier are in one cavity of the dual- cavity container and the at least one formamidine compound and the second veterinarily acceptable carrier is in a second cavity of the dual-cavity container; and wherein the first cavity is defined by a front wall and a divider wall; and the second cavity is defined by a rear wall and the divider wall.
  • the at least one 1-arylpyrazole compound is fipronil.
  • a kit for the treatment or prevention of a parasitic infestation in an animal comprising: at least one 1-arylpyrazole compound in a first veterinarily acceptable carrier, at least one formamidine compound in a second veterinarily acceptable carrier, and a multiple cavity container; wherein the at least one 1-arylpyrazole compound(s) in a first veterinarily acceptable carrier is in a first cavity of the multiple cavity container and the at least one formamidine compound(s) in a second veterinarily acceptable carrier is in a second cavity of the multiple cavity container; and wherein the first cavity is defined by a front wall and a divider wall; and the second cavity defined by a rear wall and the divider wall.
PCT/US2009/064443 2008-11-19 2009-11-13 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof WO2010059529A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
MX2011005184A MX2011005184A (es) 2008-11-19 2009-11-13 Composiciones que comprenden un aril pirazol y/o una formamidina, metodos y usos de las mismas.
RU2011124948/15A RU2011124948A (ru) 2008-11-19 2009-11-13 Композиции, включающие 1-арилпиразол сам по себе или в комбинации с формамидином, для лечения паразитарных инфекций
EP12189478.6A EP2550962B1 (en) 2008-11-19 2009-11-13 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
CA2743856A CA2743856C (en) 2008-11-19 2009-11-13 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
AU2009316899A AU2009316899B2 (en) 2008-11-19 2009-11-13 Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection
NZ592865A NZ592865A (en) 2008-11-19 2009-11-13 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
JP2011537523A JP5755143B2 (ja) 2008-11-19 2009-11-13 アリールピラゾールおよび／またはホルムアミジンを含む組成物、それらの方法ならびに使用
AP2011005959A AP3359A (en) 2008-11-19 2009-11-13 Compositions comprising 1-arylpyrazole alone or incombination with formamidine for the treatment of parasitic infection
EP09760661A EP2364147A2 (en) 2008-11-19 2009-11-13 Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection
UAA201107658A UA107654C2 (en) 2008-11-19 2009-11-13 Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment or parasitic infection
BRPI0922043-7A BRPI0922043B1 (pt) 2008-11-19 2009-11-13 Composições compreendendo um aril pirazol e/ou formamidina, métodos e usos das mesmas
KR1020117014099A KR101660068B1 (ko) 2008-11-19 2009-11-13 기생충 감염 치료를 위한 1-아릴피라졸 단독 또는 포름아미딘과의 조합을 포함하는 조성물
CN200980153974.0A CN102271672B (zh) 2008-11-19 2009-11-13 用于治疗寄生物感染的包含单独的或与甲脒组合的1-芳基吡唑的组合物
SG2011035771A SG171751A1 (en) 2008-11-19 2009-11-13 Compositions comprising an aryl pyrazole and/ or a formamidine methods and uses thereof
TW098139363A TWI505777B (zh) 2008-11-19 2009-11-19 含芳基吡唑及／或甲脒之組合物，其方法及用途
ZA2011/03618A ZA201103618B (en) 2008-11-19 2011-05-17 Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection
IL212938A IL212938A (en) 2008-11-19 2011-05-17 Kit containing fibronyl and amitraz for the treatment of animal parasites

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11603808P 2008-11-19 2008-11-19
US61/116,038 2008-11-19
US14256109P 2009-01-05 2009-01-05
US61/142,561 2009-01-05
US16738109P 2009-04-07 2009-04-07
US61/167,381 2009-04-07

Publications (2)

Publication Number Publication Date
WO2010059529A2 true WO2010059529A2 (en) 2010-05-27
WO2010059529A3 WO2010059529A3 (en) 2010-07-29

Family

ID=41667256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064443 WO2010059529A2 (en) 2008-11-19 2009-11-13 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof

Country Status (23)

Country Link
US (2) US8450357B2 (zh)
EP (2) EP2550962B1 (zh)
JP (2) JP5755143B2 (zh)
KR (1) KR101660068B1 (zh)
CN (1) CN102271672B (zh)
AP (1) AP3359A (zh)
AR (1) AR074383A1 (zh)
AU (2) AU2009316899B2 (zh)
BR (1) BRPI0922043B1 (zh)
CA (1) CA2743856C (zh)
CO (1) CO6382116A2 (zh)
CR (1) CR20110273A (zh)
ES (1) ES2781828T3 (zh)
IL (1) IL212938A (zh)
MX (1) MX2011005184A (zh)
MY (1) MY155497A (zh)
NZ (2) NZ612417A (zh)
PL (1) PL396375A1 (zh)
RU (3) RU2011124948A (zh)
SG (1) SG171751A1 (zh)
TW (1) TWI505777B (zh)
WO (1) WO2010059529A2 (zh)
ZA (2) ZA201103618B (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2347653A3 (en) * 2009-12-28 2014-02-26 Sumitomo Chemical Company, Limited Animal ectoparasite control composition
WO2015007923A1 (es) * 2013-07-18 2015-01-22 König Lab, S.L. Procedimiento de desparasitación de animales mediante la aplicación simultánea de dos o más agentes parasiticidas por vía dérmica y dispositivo para su puesta en práctica
US9622478B2 (en) 2012-10-16 2017-04-18 Solano S.P. Ltd. Topical formulations for treating parasitic infestations
US10512628B2 (en) 2016-04-24 2019-12-24 Solano S.P. Ltd. Dinotefuran liquid flea and tick treatment
US11883530B2 (en) 2013-12-20 2024-01-30 Intervet Inc. Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531186B2 (en) * 2003-12-17 2009-05-12 Merial Limited Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz
FR2909975B1 (fr) * 2006-12-13 2009-04-17 Eskiss Packaging Soc Par Actio Flacon destine a recevoir une dose determinee d'un liquide
NZ585499A (en) * 2007-11-26 2011-12-22 Merial Ltd Solvent systems for pour-on formulations for combating parasites
US9173728B2 (en) * 2008-11-19 2015-11-03 Merial Inc. Multi-cavity container having offset indentures for dispensing fluids
RU2011124948A (ru) * 2008-11-19 2012-12-27 Мериал Лимитед Композиции, включающие 1-арилпиразол сам по себе или в комбинации с формамидином, для лечения паразитарных инфекций
EP2416663A2 (en) 2009-03-18 2012-02-15 Martin Benedict George Donnelly Parasiticidal formulation
UY33443A (es) * 2010-06-19 2012-01-31 Bayer Animal Health Gmbh Preparacion que contiene ectoparasiticida para la formacion de emulsion espontanea
MX2013011954A (es) * 2011-04-15 2013-12-16 Colgate Palmolive Co Kit de cuidado bucal.
CH705153A1 (fr) * 2011-06-24 2012-12-31 Heidi Hall Mors et système pour envoyer une substance visqueuse et/ou liquide dans la bouche d'un animal.
US9034912B1 (en) * 2012-03-23 2015-05-19 Jugal K. Taneja Veterinary composition and method
EP2833867B2 (en) 2012-04-04 2023-05-10 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
US20130292414A1 (en) * 2012-05-02 2013-11-07 Spencer D. Sutherland Dispensing Device
BR112016014216B1 (pt) 2013-12-20 2022-08-30 Intervet International B.V. Usos de um composto isoxazolina
USD765520S1 (en) * 2014-01-07 2016-09-06 The Coca-Cola Company Blister package
JP6722464B2 (ja) * 2016-01-28 2020-07-15 株式会社大阪製薬 動物用害虫防除具
IL307992A (en) 2017-12-15 2023-12-01 Tarsus Pharmaceuticals Inc Parasitic formulations containing isoxazoline and methods for treating blepharitis
CA3096523C (en) * 2018-04-12 2023-07-11 Glenn Andrew Bradshaw Animal treatment apparatus, block, and method of use
JP7199653B2 (ja) * 2018-08-17 2023-01-06 住化エンバイロメンタルサイエンス株式会社 樹脂製容器入り外部寄生虫駆除剤
KR102056732B1 (ko) * 2019-07-10 2019-12-17 (주)알메디카 환자 맞춤형 약액을 수용하기 위한 일회용 약액 용기, 이를 제작하는 장치, 및 제작 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005489A2 (en) * 2006-07-05 2008-01-10 Aventis Agriculture 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US404972A (en) 1889-06-11 howard
DE404972C (de) * 1921-06-17 1924-10-28 Otto Zinsheimer Aufzugsgeruest, insbesondere fuer Dachdeckerarbeiten
US3318769A (en) 1963-05-31 1967-05-09 Shell Oil Co Resin compositions comprising organo-phosphorus pesticides
US3781355A (en) * 1969-12-12 1973-12-25 Boots Pure Drug Co Ltd Pesticidal compounds and compositions
NL160809C (nl) 1970-05-15 1979-12-17 Duphar Int Res Werkwijze ter bereiding van benzoylureumverbindingen, alsmede werkwijze ter bereiding van insekticide prepara- ten op basis van benzoylureumverbindingen.
US3864497A (en) * 1970-12-01 1975-02-04 Boots Pure Drug Co Ltd Acaricidal and insecticidal 1,5-diphenyl-3-methyl-1,3,5-triazapenta-1,4-diener
US3852416A (en) 1971-05-27 1974-12-03 L Grubb Tick and flea collar of solid solution plasticized vinylic resin-carbamate insecticide
JPS4914624A (zh) 1972-06-08 1974-02-08
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
US3818047A (en) 1972-08-07 1974-06-18 C Henrick Substituted pyrones
US4150109A (en) 1974-05-07 1979-04-17 Dick Pierre R G Devices for protecting animals from ectoparasites
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
CH604517A5 (zh) 1976-08-19 1978-09-15 Ciba Geigy Ag
JPS5338621A (en) 1976-09-16 1978-04-08 Nissan Chem Ind Ltd Miticidal composition
JPS5341428A (en) 1976-09-27 1978-04-14 Nissan Chem Ind Ltd Miticidal composition
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4134973A (en) 1977-04-11 1979-01-16 Merck & Co., Inc. Carbohydrate derivatives of milbemycin and processes therefor
GB1576393A (en) * 1977-07-01 1980-10-08 Boots Co Ltd Pesticidal compositions
JPS5444021A (en) 1977-09-10 1979-04-07 Nissan Chem Ind Ltd Miticidal composition
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4144352A (en) 1977-12-19 1979-03-13 Merck & Co., Inc. Milbemycin compounds as anthelmintic agents
JPS54101426A (en) 1978-01-24 1979-08-10 Nissan Chem Ind Ltd Miticidal composition
US4203976A (en) 1978-08-02 1980-05-20 Merck & Co., Inc. Sugar derivatives of C-076 compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS57139012A (en) 1981-02-23 1982-08-27 Sankyo Co Ltd Anthelmintic composition
US4427663A (en) 1982-03-16 1984-01-24 Merck & Co., Inc. 4"-Keto-and 4"-amino-4"-deoxy avermectin compounds and substituted amino derivatives thereof
DE3235931A1 (de) 1982-09-29 1984-03-29 Bayer Ag, 5090 Leverkusen Koeder zur bekaempfung von ungeziefer
JPS59199673A (ja) 1983-04-25 1984-11-12 Sumitomo Chem Co Ltd 含窒素複素環化合物、その製造法およびそれを有効成分とする有害生物防除剤
IL76708A (en) 1984-10-18 1990-01-18 Ciba Geigy Ag Substituted n-benzoyl-n'-(2,5-dichloro-4(1,1,2,3,3,3-hexafluoropropyloxy)-phenyl)ureas,their preparation and pesticidal compositions containing them
DE3681465D1 (zh) 1985-02-04 1991-10-24 Nihon Bayer Agrochem K.K., Tokio/Tokyo, Jp
US4620057A (en) 1985-06-07 1986-10-28 Phillips Petroleum Company Methane conversion
GB8713768D0 (en) 1987-06-12 1987-07-15 May & Baker Ltd Compositions of matter
US5232940A (en) 1985-12-20 1993-08-03 Hatton Leslie R Derivatives of N-phenylpyrazoles
US5547974A (en) 1985-12-20 1996-08-20 Rhone-Poulenc Agriculture Ltd. Derivatives of N-phenylpyrazoles
GB8531485D0 (en) 1985-12-20 1986-02-05 May & Baker Ltd Compositions of matter
US6372774B1 (en) 1985-12-20 2002-04-16 Rhone-Poulenc Agriculture Ltd. Derivatives of N-phenylpyrazoles
DE3600287A1 (de) 1986-01-08 1987-07-16 Bayer Ag 1-arylpyrazole
EP0237482A1 (de) 1986-03-06 1987-09-16 Ciba-Geigy Ag C(29)-Carbonyloxi-milbemycin-Derivate zur Bekämpfung von tier- und pflanzenparasitären Schädlingen
EP0342710B1 (en) * 1986-03-25 1993-05-19 Sankyo Company Limited Macrolide compounds, their preparation and their use
GB8613914D0 (en) 1986-06-07 1986-07-09 Coopers Animal Health Liquid formulations
ATE75745T1 (de) * 1986-07-02 1992-05-15 Ciba Geigy Ag Pestizide.
US4855317A (en) 1987-03-06 1989-08-08 Ciba-Geigy Corporation Insecticides and parasiticides
US4871719A (en) 1987-03-24 1989-10-03 Ciba-Geigy Corporation Composition for controlling parasites in productive livestock
US4874749A (en) 1987-07-31 1989-10-17 Merck & Co., Inc. 4"-Deoxy-4-N-methylamino avermectin Bla/Blb
EP0319142B1 (en) * 1987-11-03 1994-04-06 Beecham Group Plc Intermediates for the preparation of anthelmintic macrolide antibiotics
SE8802173D0 (sv) 1988-06-10 1988-06-10 Astra Ab Pyrimidine derivatives
GB8816915D0 (en) 1988-07-15 1988-08-17 May & Baker Ltd New compositions of matter
GB2220856A (en) 1988-07-18 1990-01-24 Merck & Co Inc Novel synergistic agricultural insecticidal and acaricidal combinations containing avermectin derivatives
NZ232422A (en) 1989-02-16 1992-11-25 Merck & Co Inc 13-ketal milbemycin derivatives and parasiticides
US4918085A (en) * 1989-03-02 1990-04-17 Rhone-Poulenc Ag Company Pesticidal 3-cyano-5-alkoxy-1-arylpyrazoles, compositions and use
AU631259B2 (en) 1989-12-18 1992-11-19 Ciba-Geigy Ag Formulations of benzoylphenyl ureas for combating ectoparasites
IE904606A1 (en) 1989-12-21 1991-07-03 Beecham Group Plc Novel products
CA2036147A1 (en) 1990-06-29 1991-12-30 Hiroki Tomioka A 1-pyridylimidazole derivative and its production and use
IT1243064B (it) * 1990-10-02 1994-05-23 Sarong Spa Apparecchiatura per la formatura di alveoli in nastri senza soluzione di continuita', in particolare per il confezionamento di prodotti iniettabili come supposte, ovuli o simili
NO179282C (no) 1991-01-18 1996-09-11 Rhone Poulenc Agrochimie Nye 1-(2-pyridyl)pyrazolforbindelser til kontroll av skadeinsekter
NZ247278A (en) 1991-02-12 1995-03-28 Ancare Distributors Veterinary anthelmintic drench comprising a suspension of praziquantel in a liquid carrier
US5236938A (en) * 1991-04-30 1993-08-17 Rhone-Poulenc Inc. Pesticidal 1-aryl-5-(substituted alkylideneimino)pyrazoles
WO1992022555A1 (en) 1991-06-17 1992-12-23 Beecham Group Plc Paraherquamide derivatives, precursor thereof, processes for their preparation, microorganism used and their use as antiparasitic agents
US5246255A (en) 1991-06-24 1993-09-21 Forbes Christopher B Repair flange
US5411737A (en) 1991-10-15 1995-05-02 Merck & Co., Inc. Slow release syneresing polymeric drug delivery device
MX9206034A (es) 1991-10-24 1993-05-01 Roussel Uclaf Sistema para el control de plagas.
US5345377A (en) 1992-10-30 1994-09-06 Electric Power Research Institute, Inc. Harmonic controller for an active power line conditioner
CN1079776A (zh) 1993-01-03 1993-12-22 苏州市畜牧兽医站 犬、猫专用药物洗涤剂
US5353961A (en) * 1993-01-15 1994-10-11 Reseal International Limited Partnership Dual chamber dispenser
GB9300883D0 (en) 1993-01-18 1993-03-10 Pfizer Ltd Antiparasitic agents
US5318203A (en) 1993-07-01 1994-06-07 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Dual chamber dispenser
US5714919A (en) * 1993-10-12 1998-02-03 Matsushita Electric Industrial Co., Ltd. Dielectric notch resonator and filter having preadjusted degree of coupling
US5399582A (en) 1993-11-01 1995-03-21 Merck & Co., Inc. Antiparasitic agents
JP3715994B2 (ja) 1993-12-21 2005-11-16 住友化学株式会社 害虫防除剤
AUPM969994A0 (en) 1994-11-28 1994-12-22 Virbac S.A. Equine anthelmintic formulations
US6221894B1 (en) 1995-03-20 2001-04-24 Merck & Co., Inc. Nodulisporic acid derivatives
US5962499A (en) 1995-03-20 1999-10-05 Merck & Co., Inc. Nodulisporic acid derivatives
MY113806A (en) 1995-07-21 2002-05-31 Upjohn Co Antiparasitic marcfortines and paraherquamides
US6230935B1 (en) 1995-07-28 2001-05-15 Colgate-Palmolive Company Dual chamber pump dispenser
FR2739255B1 (fr) * 1995-09-29 1998-09-04 Rhone Merieux Composition antiparasitaire pour le traitement et la protection des animaux de compagnie
US5817688A (en) * 1995-12-19 1998-10-06 Rhone-Poulenc Inc. Pesticidal 1-arylpyrazole derivatives
US5922885A (en) 1995-12-19 1999-07-13 Rhone-Poulenc Inc. Pesticidal 1-arylpyrazole derivatives
ES2191076T3 (es) 1995-12-19 2003-09-01 Bayer Cropscience Sa Nuevos derivados de 1-aril-pirazol y su empleo como plaguicidas.
SE517612C2 (sv) 1995-12-20 2002-06-25 Rhone Poulenc Agrochimie Användning av 5-amino-4-etylsulfinyl-1-arylpyrazol föreningar som pesticider
DE19548872A1 (de) * 1995-12-27 1997-07-03 Bayer Ag Synergistische insektizide Mischungen
US6413542B1 (en) 1996-03-29 2002-07-02 Merial Direct pour-on antiparasitic skin solution and methods for treating, preventing and controlling myasis
IE80657B1 (en) * 1996-03-29 1998-11-04 Merial Sas Insecticidal combination to control mammal fleas in particular fleas on cats and dogs
FR2752525B1 (fr) 1996-08-20 2000-05-05 Rhone Merieux Procede de lutte contre les myiases des cheptels bovins et ovins et compositions pour la mise en oeuvre de ce procede
US6010710A (en) * 1996-03-29 2000-01-04 Merial Direct pour-on skin solution for antiparasitic use in cattle and sheep
US5885607A (en) 1996-03-29 1999-03-23 Rhone Merieux N-phenylpyrazole-based anti-flea and anti-tick external device for cats and dogs
DK1175902T3 (da) * 1996-07-15 2005-12-19 Sankyo Co Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose
US6426333B1 (en) * 1996-09-19 2002-07-30 Merial Spot-on formulations for combating parasites
US6998131B2 (en) 1996-09-19 2006-02-14 Merial Limited Spot-on formulations for combating parasites
FR2753377B1 (fr) * 1996-09-19 1999-09-24 Rhone Merieux Nouvelle association parasiticide a base de 1-n-phenylpyra- zoles et de lactones macrocycliques endectocides
JP4126621B2 (ja) * 1996-11-25 2008-07-30 日本農薬株式会社 殺虫・殺ダニ剤
US6069157A (en) * 1997-11-25 2000-05-30 Pfizer Inc. Parasiticidal compounds
GB9625045D0 (en) 1996-11-30 1997-01-22 Pfizer Ltd Parasiticidal compounds
SK285866B6 (sk) 1996-12-24 2007-10-04 Rhone-Poulenc Agro 1-Arylpyrazolové zlúčeniny, pesticídne prostriedky obsahujúce tieto zlúčeniny ako účinné látky a spôsob ničenia škodcov
US6350771B1 (en) 1996-12-24 2002-02-26 Rhone-Poulenc, Inc. Pesticidal 1-arylpyrazoles
WO1998039972A1 (en) 1997-03-11 1998-09-17 Rhone-Poulenc Agro Pesticidal combination
KR100500181B1 (ko) 1997-04-07 2005-07-12 니혼노야쿠가부시키가이샤 피라졸 유도체, 이의 제조방법, 중간체 및 이를 유효 성분으로서 함유하는 유해 생물 방제제
JPH10324605A (ja) 1997-05-22 1998-12-08 Nippon Nohyaku Co Ltd 殺ダニ剤組成物及びその使用方法
USD404972S (en) 1997-06-09 1999-02-02 Rodgers Jr Garnett J Reusable dual chamber dispenser
US6207647B1 (en) 1997-07-18 2001-03-27 Smithkline Beecham Corporation RatA
US6057355A (en) 1997-08-05 2000-05-02 Rhone-Poulenc Inc. Pesticidal combination
TR200000517T2 (tr) * 1997-08-26 2000-08-21 Hoechst Marion Roussel, Inc. Piperidinoalkanol-Konjesyon azaltıcıdan oluşan kombinasyona yönelik farmasötik kompozisyon.
CN1205921C (zh) * 1997-12-03 2005-06-15 麦克公司 含有氢化蓖麻油的长效注射制剂
AUPP105597A0 (en) 1997-12-19 1998-01-15 Schering-Plough Animal Health Limited Solvent/surfactant insecticidal pour-on formulation
US6090751A (en) 1998-06-10 2000-07-18 Rhone-Poulenc Agro Emulsifiable concentrate comprising an insecticidal 1-arylpyrazole
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
CO5210925A1 (es) * 1998-11-17 2002-10-30 Novartis Ag Derivados de diamino nitroguanidina tetrasustituidos
US6161729A (en) 1998-12-14 2000-12-19 Unilever Home & Personal Care Usa, Division Of Conopco Dual chamber dispenser
US6350922B1 (en) 1998-12-18 2002-02-26 The Dow Chemical Company Process for making 2,3-dihalopropanols
NZ514000A (en) 1999-03-12 2003-04-29 Basf Ag Synergistic insecticidal compositions
DE60031527T2 (de) 1999-05-28 2007-06-06 Sarong S.P.A., Reggiolo Verfahren und anlage zum herstellen von zweikammerbehältern
GB9916052D0 (en) * 1999-07-08 1999-09-08 Pfizer Ltd Anthelmintic compositions
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
CN1402713A (zh) 1999-12-02 2003-03-12 阿温提斯作物科学股份有限公司 控制动物中的节肢动物
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
PE20011289A1 (es) 2000-04-07 2001-12-21 Upjohn Co Composiciones antihelminticas que comprenden lactonas macrociclicas y espirodioxepinoindoles
US6260735B1 (en) 2000-05-12 2001-07-17 Colgate-Palmolive Company Uniform dispensing dual chamber sachet
CA2311862C (en) 2000-06-16 2006-10-10 Gary O. Maupin Control of arthropod vectors of parasitic diseases
CA2311881C (en) 2000-06-16 2007-08-28 Gary O. Maupin Control of arthropods in rodents
ES2277923T3 (es) * 2000-07-06 2007-08-01 Sumitomo Chemical Company, Limited Insecticidas.
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US6399786B1 (en) 2000-07-14 2002-06-04 Merck & Co., Inc. Nonacyclic nodulisporic acid derivatives
NZ505779A (en) * 2000-07-14 2003-06-30 Akzo Nobel Nv Pesticidal composition containing insect growth regulating (IGR) insecticide in an aromatic hydrocarbon and/or pyrrolidone and/or propylene glycol monoalkyl ether solvent system
WO2002058690A2 (en) 2001-01-26 2002-08-01 Chugai Seiyaku Kabushiki Kaisha Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
AR036872A1 (es) 2001-08-13 2004-10-13 Du Pont Compuesto de antranilamida, composicion que lo comprende y metodo para controlar una plaga de invertebrados
US20050119489A1 (en) 2001-12-28 2005-06-02 Ladouceur Gaetan H. 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
US7517877B2 (en) 2002-03-05 2009-04-14 Merial Limited 5-substituted-alkylaminopyrazole derivatives as pesticides
US7001889B2 (en) 2002-06-21 2006-02-21 Merial Limited Anthelmintic oral homogeneous veterinary pastes
TW200409760A (en) 2002-09-11 2004-06-16 Novartis Ag Organic compounds
US7368435B2 (en) * 2002-09-12 2008-05-06 Summit Vetpharm, Llc Topical endoparasiticide and ectoparasiticide formulations
US7345092B2 (en) * 2002-09-12 2008-03-18 Summit Vetpharm, Llc High concentration topical insecticides containing pyrethroids
US7906128B2 (en) 2002-10-21 2011-03-15 Wyeth Llc Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
CN1719974A (zh) 2002-12-03 2006-01-11 拜尔作物科学股份有限公司 杀虫的5－(酰基氨基)吡唑衍生物
ITMO20030030A1 (it) 2003-02-07 2004-08-08 Sarong Spa Apparati e metodi per ottenere contenitori, e contenitore
US7262214B2 (en) 2003-02-26 2007-08-28 Merial Limited 1-N-arylpyrazole derivatives in prevention of arthropod-borne and mosquito-borne diseases
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US6883195B1 (en) * 2003-12-11 2005-04-26 Hans P. Gustavsen Removable rescue board patient support
US7531186B2 (en) * 2003-12-17 2009-05-12 Merial Limited Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz
KR101197482B1 (ko) 2004-03-05 2012-11-09 닛산 가가쿠 고교 가부시키 가이샤 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제
WO2005094330A2 (en) 2004-03-29 2005-10-13 Merial Limited Pipette/applicator
US20050234119A1 (en) 2004-04-16 2005-10-20 Soll Mark D Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals
PE20060785A1 (es) 2004-10-08 2006-09-19 Wyeth Corp Composiciones de amitraz
CA2587429C (en) 2004-12-07 2013-03-05 Merial Limited 5-aminopyrazole derivatives as pesticidal compounds
US20080003282A1 (en) 2005-04-18 2008-01-03 Soll Mark D Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals
EP1764095A1 (en) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
EP1965645A2 (en) 2005-12-14 2008-09-10 E.I. Du Pont De Nemours And Company Isoxazolines for controlling invertebrate pests
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
ITMO20060395A1 (it) 2006-11-29 2008-05-30 Sarong Spa Contenitore, apparato e metoo per la sua produzione
TW200846029A (en) 2007-02-09 2008-12-01 Wyeth Corp High dose, long-acting ectoparasiticide for extended control
RU2009141185A (ru) 2007-04-10 2011-05-20 Байер КропСайенс АГ (DE) Инсектицидные производные арилизоксазолина
RS55271B1 (sr) 2007-05-15 2017-02-28 Merial Sas Ariloazol-2-il cijanoetilamino jedinjenja, postupci dobijanja i postupci njihove primene
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
KR101714291B1 (ko) 2007-06-27 2017-03-08 이 아이 듀폰 디 네모아 앤드 캄파니 동물 해충 방제 방법
US8440633B2 (en) 2007-06-29 2013-05-14 Ah Usa 42 Llc Anthelmintic combination
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
RU2011124948A (ru) * 2008-11-19 2012-12-27 Мериал Лимитед Композиции, включающие 1-арилпиразол сам по себе или в комбинации с формамидином, для лечения паразитарных инфекций

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005489A2 (en) * 2006-07-05 2008-01-10 Aventis Agriculture 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2364147A2 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2347653A3 (en) * 2009-12-28 2014-02-26 Sumitomo Chemical Company, Limited Animal ectoparasite control composition
US9622478B2 (en) 2012-10-16 2017-04-18 Solano S.P. Ltd. Topical formulations for treating parasitic infestations
WO2015007923A1 (es) * 2013-07-18 2015-01-22 König Lab, S.L. Procedimiento de desparasitación de animales mediante la aplicación simultánea de dos o más agentes parasiticidas por vía dérmica y dispositivo para su puesta en práctica
US11883530B2 (en) 2013-12-20 2024-01-30 Intervet Inc. Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
US10512628B2 (en) 2016-04-24 2019-12-24 Solano S.P. Ltd. Dinotefuran liquid flea and tick treatment

Also Published As

Publication number Publication date
AR074383A1 (es) 2011-01-12
IL212938A (en) 2016-11-30
US20100125097A1 (en) 2010-05-20
CO6382116A2 (es) 2012-02-15
US8450357B2 (en) 2013-05-28
KR20110084997A (ko) 2011-07-26
EP2364147A2 (en) 2011-09-14
SG171751A1 (en) 2011-07-28
AU2015221450A1 (en) 2015-09-17
BRPI0922043A2 (pt) 2015-12-22
AP3359A (en) 2015-07-31
US20130256170A1 (en) 2013-10-03
CR20110273A (es) 2011-08-03
EP2550962B1 (en) 2019-10-30
ZA201501598B (en) 2017-04-26
RU2011124948A (ru) 2012-12-27
KR101660068B1 (ko) 2016-09-26
US8921408B2 (en) 2014-12-30
JP2015013899A (ja) 2015-01-22
RU2608906C2 (ru) 2017-01-26
AP2011005959A0 (en) 2011-10-31
BRPI0922043B1 (pt) 2019-04-24
TWI505777B (zh) 2015-11-01
EP2550962A3 (en) 2013-10-23
TW201029574A (en) 2010-08-16
AU2009316899A1 (en) 2010-05-27
CN102271672A (zh) 2011-12-07
PL396375A1 (pl) 2012-04-23
CA2743856A1 (en) 2010-05-27
CN102271672B (zh) 2015-02-04
JP5755143B2 (ja) 2015-07-29
IL212938A0 (en) 2011-07-31
CA2743856C (en) 2018-02-13
RU2013128359A (ru) 2014-12-27
NZ592865A (en) 2013-08-30
RU2013144546A (ru) 2015-04-10
JP2012509327A (ja) 2012-04-19
AU2009316899B2 (en) 2015-08-20
ES2781828T3 (es) 2020-09-08
ZA201103618B (en) 2016-07-27
NZ612417A (en) 2015-02-27
WO2010059529A3 (en) 2010-07-29
MY155497A (en) 2015-10-30
EP2550962A2 (en) 2013-01-30
MX2011005184A (es) 2011-07-28

Similar Documents

Publication Publication Date Title
AU2009316899B2 (en) Compositions comprising 1-arylpyrazole alone or in combination with formamidine for the treatment of parasitic infection
CA2793880C (en) Parasiticidal compositions comprising multiple active agents, methods and uses thereof
US9173728B2 (en) Multi-cavity container having offset indentures for dispensing fluids
AU2017225029A1 (en) Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof
AU2015202084B2 (en) Parasiticidal compositions comprising multiple active agents, methods and uses thereof
AU2016247183B2 (en) Parasiticidal compositions comprising multiple active agents, methods and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980153974.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09760661

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2743856

Country of ref document: CA

Ref document number: 592865

Country of ref document: NZ

Ref document number: 2009316899

Country of ref document: AU

Ref document number: 12011500933

Country of ref document: PH

Ref document number: MX/A/2011/005184

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 212938

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: P.396375

Country of ref document: PL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011537523

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: CR2011-000273

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2009760661

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009316899

Country of ref document: AU

Date of ref document: 20091113

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13126016

Country of ref document: CO

Ref document number: 11072888

Country of ref document: CO

Ref document number: 14155170

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 4613/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117014099

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011124948

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0922043

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110519